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A PATIENT-CENTERED APPROACH TO
HEALTH CARE FRAUD RECOVERY
JOAN H. KRAUSE*
This Article begins with a simple premise: Health care fraud hurts
patients. From that premise flows a simple corollary: efforts to combat
health care fraud should, if possible, remedy this patient harm. Despite its
intuitive appeal, this syllogism does not represent current practice. Funds
recovered through health care fraud enforcement are distributed to the
Medicare Trust Fund, to the federal agencies that investigate and prosecute
health care fraud, and to private parties who initiate suits on the
government's behalf under the civil False Claims Act'-but rarely to
patients who may have been harmed by the conduct. While focusing
enforcement efforts on returning funds to the Federal Treasury clearly helps
to assure that the federal health care programs 2 remain solvent and continue
to provide care to beneficiaries in the aggregate, it offers little solace to
injured individuals.
This approach stands in marked contrast to efforts to make the United
States health care system more "patient-centered." In 2001, the Institute of
Medicine's Committee on Quality of Health Care in America identified
"patient-centeredness" as one of the six health care aims for the next
century, "focus[ing] on the patient's experience of illness and health care
and on the systems that work or fail to work to meet individual patients'
* George Butler Research Professor of Law and Co-Director, Health Law & Policy
Institute, University of Houston Law Center. I am grateful to Marcilynn Burke, Gerry
Moohr, Richard Saver, and Sandra Guerra Thompson for their assistance with this Article,
and to Nadia Mosqueda for her invaluable word-processing skills. Portions of this article
were adapted from Joan H. Krause, Healthcare Fraud and Quality of Care: A Patient-
Centered Approach, 37 J. HEALTH L. 161 (2004).
' See 31 U.S.C. §§ 3729-33 (2000).
2 As used in the fraud statutes, "Federal health care program" includes "any plan or
program that provides health benefits, whether directly, through insurance, or otherwise,
which is funded directly, in whole or in part, by the United States Government" with the
exception of the Federal Employees Health Benefit Program, as well as state-funded health
care programs. See 42 U.S.C. § 1320a-7b(f)(1) (2000).
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needs."3  While advocates initially focused their efforts on clinical
practice-emphasizing respect for patients, the provision of honest and
complete information, physical comfort, and emotional support for patients
and their familiesa-these concepts have grown to encompass systemic
structural concerns as well. A patient-centered approach to access to health
care makes "serving the practical health care needs of patients (1) the focal
point of the health care system, (2) the paramount responsibility of health
professionals, and (3) the primary role of private and public financing [of]
health care."5 A health care fraud enforcement system that assures large
3 COMM. ON QUALITY OF HEALTH CARE IN AM., INST. OF MED., CROSSING THE QUALITY
CHASM: A NEW HEALTH SYSTEM FOR THE 21ST CENTURY 48 (2001); see also THROUGH THE
PATIENT'S EYES: UNDERSTANDING AND PROMOTING PATIENT-CENTERED CARE 5 (Margaret
Gerteis et al. eds., 1993) (focusing "on the patient's experience of illness and health care and
the systems that work, and fail to work, to meet patients' needs, as they define them").
4 See THROUGH THE PATIENT'S EYES: UNDERSTANDING AND PROMOTING PATIENT-
CENTERED CARE, supra note 3, at 5-11 (defining dimensions of patient-centered care).
5 Laura D. Hermer & William J. Winslade, Access to Health Care in Texas: A Patient-
Centered Perspective, 35 TEx. TECH. L. REv. 33, 34 (2004) (emphasis added). Even
Congress has jumped on the patient-centered care bandwagon. See Bill Frist, Speeches:
Frist Outlines Plan for "Putting the Patient at the Heart of Health Care, " July 23, 2005,
available at http://frist. senate.gov/index.cfm?FuseAction=Speeches.Detail&Speech id
=254&Month=7&Year=2005 (text of speech by Sen. Bill Frist to Commonwealth Club of
California).
Patient-centered care is in many ways the clinical counterpart to therapeutic
jurisprudence, "the study of the use of the law to achieve therapeutic objectives." David B.
Wexler, An Introduction to Therapeutic Jurisprudence, in THERAPEUTIC JURISPRUDENCE:
THE LAW AS THERAPEUTIC AGENT 4 (David B. Wexler ed., 1990). The core insight of
therapeutic jurisprudence is that the legal system-both in terms of substantive legal rules
and systemic structure-may have effects that are more or less "healing" in nature. Id at 14
(arguing that "the legal system itself... should be examined, and perhaps restructured, to
maximize its therapeutic aspects and to minimize its anti-therapeutic aspects"). Although its
genesis was in the area of mental health law, the theory has been applied to a variety of legal
issues including tort suits and appellate advocacy. See, e.g., id at 4 (discussing application
of theory to mental health law); Harold S. Kaplan, Benefiting from the "Gift of Failure":
Essentials for an Event Reporting System, 24 J. LEGAL MED. 29, 42 (2003) (discussing
therapeutic failures of malpractice litigation); Daniel W. Shuman, Making the World a Better
Place Through Tort Law?: Through the Therapeutic Looking Glass, 10 N.Y.L. SCH. J. HUM.
RTS. 739 (1993) (discussing application of theory to tort law); Christopher Slobogin,
Therapeutic Jurisprudence: Five Dilemmas to Ponder, 1 PSYCHOL. PUB. POL'Y & L. 193
(1995) (identifying issues that may arise in applying theory to practice); David B. Wexler,
Introduction: Therapeutic Jurisprudence in the Appellate Arena, 24 SEATTLE U. L. REV. 217,
217 (2000) (discussing "the use of therapeutic jurisprudence in the appellate courts"). In the
health law literature, recent scholarship by academics such as Mark Hall has used therapeutic
jurisprudence as the basis for thought-provoking discussions of the role of trust in the health
care system. See generally M. Gregg Bloche, Trust and Betrayal in the Medical
Marketplace, 55 STAN. L. REV. 919 (2002); Robert Gatter, Faith, Confidence, and Health
Care: Fostering Trust in Medicine Through Law, 39 WAKE FOREST L. REV. 395 (2004);
Mark A. Hall, Law, Medicine, and Trust, 55 STAN. L. REV. 463 (2002). Despite anecdotal
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monetary recoveries for the Federal fisc but makes no attempt to
compensate injured beneficiaries does not achieve these goals. In short,
current health care fraud recoveries are not patient-centered.
The reasons for this failure are complex, and derive both from the
factual context in which health care fraud occurs and from the traditional
white collar crime enforcement framework. In large part, health care fraud
recovery is not patient-centered because patients are not viewed as the
victims of the fraud; that distinction instead belongs to the federal
government, the ultimate payer under the federal health care programs.
Consistent with that view, the federal statutes most commonly invoked in
fraud cases channel recoveries to the federal coffers rather than directing
compensation to injured individuals. Indeed, to the extent the government's
primary interest in prosecuting health care fraud derives from its role as a
defrauded payer, rather than as the more general protector of its citizenry,
individualized compensation would appear to be unnecessary.6 This focus
on financial harm to the government is reinforced by situating health care
fraud within the context of white collar crime, an area of law that focuses
almost exclusively on economic harm.7 In short, the recognition that health
care fraud harms individual patients in ways that merit compensation-
particularly if such harm is non-financial in nature--does not fit into the
dominant conceptual model of health care fraud.
Part I of this Article explores the varied ways in which patients are
harmed by fraudulent health care activities. Part II analyzes barriers to
patient compensation under current law, addressing not only limitations on
the disposition of recovered funds but also the conceptual difficulties posed
by the white collar crime framework. Part III discusses recent
developments at the state and federal levels, and explores compensation
mechanisms common in consumer protection cases to determine whether
they could be imported into the health care fraud context. The Article
concludes that while there may be good reasons not to convert the entire
health care fraud enforcement scheme to a patient-centered model, it
nevertheless should be possible to reduce existing barriers to compensating
patient harm.
evidence, this approach does not appear to have been applied in detail to the topic of health
care fraud-perhaps indicating a fruitful area for future study.
6 Note, however, that powerful statutes also permit federal prosecution of private health
care fraud in the absence of federal harm as long as jurisdictional requirements are met, thus
invoking the federal government's more traditional role as protector. See, e.g., 18 U.S.C, §
1341 (2000) (mail fraud); id. § 1343 (wire fraud); id. § 1347 (health care fraud).
7 See, e.g., J. Kelly Strader, The Judicial Politics Of White Collar Crime, 50 HASTINGS
L.J. 1199, 1204-14 (1999) (discussing definitions of white collar crime).
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1. HEALTH CARE FRAUD AND PATIENT HARM
Health care fraud encompasses activities by a wide range of actors. It
includes fraud by and upon health care professionals, health care
institutions, health insurers and managed care companies, manufacturers of
prescription drugs and other health care supplies, and even patients. 8 When
such activities occur in the federal health care programs, such as Medicare
and Medicaid, they are subject to a broad array of civil, criminal, and
administrative statutes. 9 Yet, virtually all of these provisions consider the
ultimate victim of the fraud to be the federal government, rather than the
individual patient. As a result, health care fraud is largely considered a
"bloodless" form of wrongdoing, an image reinforced by characterizations
of such fraud as a stereotypical white collar crime.' ° White collar crimes
are thus the opposite of "street crimes" in which money and property are
taken by violence or the threat thereof." In health care, these principles
evoke images of highly trained physicians and executives misusing their
positions and professional skills for personal financial gain, accomplished
through deceptive yet nonviolent tactics such as falsifying bills for services.
8 See, e.g., Sharon L. Davies & Timothy Stolzfus Jost, Managed Care: Placebo or
Wonder Drug for Health Care Fraud and Abuse?, 31 GA. L. REv. 373, 383-84 (1997)
(describing potential for fraud in relationships between health care "consumers, purchasers,
providers, and intermediaries"); Joan H. Krause, A Conceptual Model of Health Care Fraud
Enforcement, 12 J.L. & POL'Y 55, 64-81 (2003) [hereinafter Krause, A Conceptual Model]
(describing industries affected by recent health care fraud initiatives). In the federal health
care programs, the term "provider" technically refers to institutional entities, such as
hospitals, home health agencies, and nursing homes. 42 U.S.C. § 1395x(u) (2000) (defining
"provider of services"). Because they face similar fraud liability, this Article will use the
term "health care provider" to refer more broadly to both individual health care professionals
and institutional health care entities. See DEP'T. OF HEALTH & HUMAN SERVS., SPECIAL
ADVISORY BULLETIN: PRACTICES OF BUSINESS CONSULTANTS 1 n.1 (2001), available at
http://oig.hhs.gov/fraud/docs/alertsandbulletins/consultants.pdf (using the term to include
"providers, suppliers, and practitioners that provide items or services payable in whole or in
part by a Federal health care program").
9 See, e.g., 42 U.S.C. § 1320a-7 (2000) (exclusion from federal health care programs); id.
§ 1320a-7a (civil monetary penalties applicable to federal health care programs); id. §
1320a-7b(b) (Medicare & Medicaid Anti-Kickback Statute); id. § 1395nn (limitations on
self-referrals).
10 See Pamela H. Bucy, Fraud by Fright: White Collar Crime by Health Care Providers,
67 N.C. L. REv. 857, 870-71 (1989) [hereinafter Bucy, Fraud by Fright] (noting that health
care fraud shares essential features of white collar crime).
I See, e.g., Darryl K. Brown, Cost-Benefit Analysis in Criminal Law, 92 CAL. L. REv.
325, 342 (2004) ("In criminal law, street crime (theft and violent crime) is especially vivid
and frightful for most people. In contrast, white collar crimes, such as financial frauds in
which many victims lose small amounts, seem much less threatening. Compared to
corporate crime risks, street crime risks are more vivid.").
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The victim-if the term even applies-is a hapless federal bureaucracy that
serves as easy prey for unscrupulous individuals.
Not surprisingly, public statements by prosecutors suggest a zero-
tolerance approach to those who take advantage of the federal health care
programs. In commenting on a recent pharmaceutical settlement, for
example, the United States Attorney for the Eastern District of
Pennsylvania stated,
This wasn't a mistake. It was a marketing strategy. The result was that programs
created to provide healthcare to the poorest among us were actually paying more for
drugs than those who have private health insurance. There is a point at which pursuit
of market share crosses the line that separates competition and illegal conduct. This
case serves as an example that the consequences of stepping over that line can be
costly.12
Where the federal health care programs are viewed as suffering the greatest
losses, it is logical to concentrate enforcement efforts on reimbursing those
programs.
But the federal government is not the only victim of fraudulent
activities. Health care fraud also causes significant harm to patients-harm
that may be financial, physical, or less tangible in nature. Although initially
slow to recognize these effects, prosecutors and policymakers have now
embraced the goal of "patient protection" as a key justification for fraud
enforcement. Yet despite this rhetoric, the financial model of health care
fraud recovery has not changed accordingly. And while returning funds to
the federal Treasury helps to assure that the federal health care programs
remain able to provide care to beneficiaries in the aggregate, this approach
fails to remedy harm to individual patients.
A. HARM TO THE FEDERAL GOVERNMENT
Health care fraud became a key priority for federal law enforcement
officials in the 1990's.13 The motivation for these efforts is clear: As the
authors of one treatise note, health care fraud is "where the money is."
14
For a sense of just how much money is at stake, note that the first
12 Press Release, U.S. Attorney's Office, Schering-Plough to Pay $345 Million to
Resolve Criminal & Civil Cases: Schering to Admit Paying Kickback in Exchange For
Preferred Treatment - Will Also Settle False Claims Liability (July 30, 2004), available at
http://www.usdoj.gov/opa/pr/2004/July/04_civ523.htm.
13 In fact, former Attorney General Janet Reno identified health care fraud as her
"number two priority," second only to violent crime. ANNUAL REPORT OF THE ATTORNEY
GENERAL OF THE UNITED STATES (1994), available at http://www.usdoj.gov/ag/
annualreports/ar94/finalag.txt.
14 ROBERT FABRIKANT ET AL., HEALTH CARE FRAUD: ENFORCEMENT AND COMPLIANCE 1-3
(2004) (paraphrasing statements made by infamous bank robber Willie Sutton).
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comprehensive audit of Medicare fee-for-service payments found that more
than $23 billion had been paid out improperly in fiscal year 1996 alone.15
Although the numbers have improved each year, auditors estimate that the
Medicare program still paid $12.1 billion in improper claims in fiscal year
2005, an error rate of 5.2 percent.1 6  Given ongoing concerns over the
solvency of the Medicare program, particularly once the so-called "Baby
Boomers" become eligible, policymakers may view health care fraud
recoveries as a means to offset escalating program costs without raising
taxes, reducing the scope of benefits, or otherwise incurring the wrath of the
powerful aging lobby.
17
Health care fraud is actionable under a wide range of federal criminal,
civil, and administrative statutes. Some of these laws, such as the Medicare
and Medicaid Anti-Kickback Statute, the "Stark Law" prohibition on
physician self-referral, and the provisions governing exclusion from the
federal health care programs, specifically target improper health care
activities. 18  Others, such as the civil and criminal false claims
prohibitions,' 9 apply more broadly to all entities that transact business with
15 See DEP'T OF HEALTH & HUMAN SERVS., OFFICE OF THE INSPECTOR GEN., IMPROPER
FISCAL YEAR 2001 MEDICARE FEE-FOR-SERVICE PAYMENTS, No. A-17-01-02002, at 1 (2002),
available at http://oig.hhs.gov/oas/reports/cms/aO102002.pdf (acknowledging that 2002 error
rate represented a significant reduction from the $23.2 billion in improper payments
identified in 1996, the first year such audits were conducted).
16 Centers for Medicare & Medicaid Services, Improper Medicare FFS Payment Short
Report (Web Version) for November 2005, https://www.cms.hhs.gov/
apps/er report/preview erreport.asp?from=public&which=short&reportlD=3&tab=2 (last
visited Dec. 12, 2005). Of course, it is not clear that all such payments constitute fraud
rather than errors or good faith disagreements. See David A. Hyman, HIPAA and Health
Care Fraud: An Empirical Perspective, 22 CATO J. 151, 162 (2002) (arguing that these
audits are not designed to measure fraud).
17 See, e.g., OFFICE OF MANAGEMENT AND BUDGET, MID-SESSION REVIEW: MEDICARE
TRUST FUNDS (2003), available at http://www.whitehouse.gov/omb/budget/fy2002/
msr03.html (projecting Medicare shortfalls through 2011); Jonathan W. Emord, Murder by
Medicare: The Demise of Solo and Small Group Medical Practices, 21-3 REGULATION 31,
32-33 (1998) (arguing that the "Medicare enforcement scheme . . . seeks to expand
definitions of improper billing, fraud, and abuse as a means to help Medicare recoup funds
from physicians," with the result that "Congress has been able to take credit for a broad array
of seemingly ever-expanding federally funded benefits and for holding down costs, while not
being held politically accountable for the program's adverse effects on medical practices and
health care markets").
"S See 42 U.S.C. § 1320a-7 (2000) (exclusion from federal health care programs); id. §
1320a-7a (civil monetary penalties applicable to federal health care programs); id. § 1320a-
7b(b) (Medicare & Medicaid Anti-Kickback Statute); id. § 1395nn (limitations on self-
referrals). For a detailed discussion of these statutes, see Krause, A Conceptual Model,
supra note 8, at 64-81.
19 See 18 U.S.C. §§ 286-87 (2000) (criminal false claims provisions); 31 U.S.C. §§ 3729-
33 (2000) (Civil False Claims Act).
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the federal government. Health care fraud also may be prosecuted under
broad federal criminal statutes, such as mail and wire fraud, conspiracy, and
the Racketeer Influenced and Corrupt Organizations Act ("RICO"), 20 which
prohibit improper conduct regardless of the industry in which it occurs.
The current centerpiece of the government's anti-fraud efforts is the
Civil False Claims Act ("FCA"), a Civil War-era statute that prohibits the
knowing submission of false or fraudulent claims to the federal
government. 21 Because violators are subject to a civil penalty of $5,500 to
$11,000 per claim, plus three times the amount of damages sustained by the
government,22 repeated submission of bills containing small increments of
fraud quickly leads to astronomical aggregate liability.23 Moreover, the
FCA's unique qui tam provisions permit private whistleblowers (known as
"relators") who sue on the government's behalf to retain fifteen to thirty
percent of the proceeds of the suit---creating a powerful incentive for
private parties to police their neighbors in the health care market.24 The
number of health care FCA suits has grown exponentially since
amendments in 1986 made it more lucrative to pursue qui tam actions, and
health care qui tam suits now eclipse those in other areas of government
25
contracting.
20 See 18 U.S.C. § 371 (conspiracy); id. §§ 1341, 1343, 1346 (mail and wire fraud); id.
§§ 1961-62 (RICO). RICO provides for both criminal and civil causes of action. See id. §
1964 (setting forth civil remedies).
21 31 U.S.C. §§ 3729-33 (2000). The law was enacted in 1863 in response to reports of
"rampant fraud" perpetrated on the United States military during the Civil War. See S. REP.
No. 99-345, at 8 (1986), as reprinted in 1986 U.S.C.C.A.N. 5266, 5273 (noting history of
False Claims Act). The most commonly invoked FCA cause of action applies where: (1) a
defendant presents (or causes to be presented) a claim for payment or approval; (2) the claim
is false or fraudulent; and (3) the defendant's acts are undertaken "knowingly." 31 U.S.C. §
3729(a)(1). "Knowingly" includes not only actual knowledge, but also deliberate ignorance
and reckless disregard of truth or falsity. See id. § 3729(b). An actionable "claim" includes
"any request or demand ... for money or property" if any portion thereof comes from the
federal government. Id. § 3729(c).
22 See 31 U.S.C. § 3729(a)(7) (listing statutory penalties and treble damages); 28 C.F.R.
§ 85.3(a)(9) (2005) (increasing statutory penalties by 10% for inflation).
23 In United States v. Krizek, for example, a psychiatrist was alleged to have submitted
8002 false claims, each inflated by approximately $30; assessing penalties of $10,000 per
claim, the government sued for $81 million dollars. 111 F.3d 934 (D.C. Cir. 1997); see also
Timothy Stoltzfus Jost & Sharon L. Davies, The Empire Strikes Back: A Critique of the
Backlash Against Fraud and Abuse Enforcement, 51 ALA. L. REv. 239, 260 (1999) (noting
that "[e]ven if individually quite small, astronomical sums are quickly reached").
24 See, e.g., 31 U.S.C. §§ 3730(b), (d) (noting that a private person who brings a civil
action may potentially receive fifteen to thirty percent of the proceeds of the suit).
25 By 1998, 61% of the filed qui tam cases involved the federal health care programs,
compared to only twelve percent in 1987. See FRIED, FRANK, HARRIS, SHRIVER & JACOBSEN
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In response to growing concerns about the magnitude of health care
fraud, the Health Insurance Portability and Accountability Act of 1996
("HIPAA")2 6 made significant changes to federal law enforcement
authority. In addition to creating new criminal causes of action," HIPAA
required that more funds be appropriated to the federal agencies with
jurisdiction over health care fraud, particularly the Department of Justice
("DOJ") and the Department of Health and Human Services ("HHS")
Office of the Inspector General ("OIG"). A key aspect of this effort was the
creation of a "Fraud and Abuse Control Program," designed to coordinate
federal, state, and local health care fraud enforcement efforts.28 The
centerpiece of the Program is the "Fraud and Abuse Control Account,"
which funds health care fraud inspections, investigations, and prosecutions
undertaken by the DOJ and OIG.29 HIPAA set fiscal year 1997 Control
Account appropriations at $104 million, with an increase of up to 15
percent per year through fiscal year 2003.30
To a certain extent, these investments have paid off. The DOJ
recovered more than $1.4 billion in civil fraud suits in fiscal year 2005, with
$1.1 billion of that amount attributed to health care fraud cases.3' While
this certainly counts as progress, it represents merely the proverbial drop in
the bucket in the face of almost $20 billion in improper payments each year.
Viewed as a return on investment, however, the picture is decidedly more
cheerful: Taxpayers Against Fraud, a nonprofit organization that promotes
the use of the FCA to combat fraud, has estimated that "for every dollar
spent to investigate and prosecute health care fraud in civil cases, the
federal government receives nearly thirteen dollars back in return. 32 With
LLP, Qui TAM FCA Statistics, available at http://www.fthsj.com/quitam/fcastats.htm (last
visited Feb. 23, 2006).
26 Pub. L. No. 104-191, 110 Stat. 1937 (1996).
27 Id. at 241-49 (revising criminal law provisions relating to health care fraud) (codified
as amended in scattered sections of 18 U.S.C., including, e.g., 18 U.S.C. § 247 (2000)
(injunctive relief relating to health care offenses), id. § 669 (theft or embezzlement in
connection with health care), id. § 1035 (false statements relating to health care matters), id.
§ 1347 (health care fraud), id § 1518 (obstruction of criminal investigations of health care
offenses)).
28 See 42 U.S.C. § 1320a-7c (2000) (establishing program).
29 Id. § 1395i(k)(3) (describing appropriations to the account).
30 Id. § 1395i(k)(3)(A)-(B) (setting out the maximum amounts available for
appropriation).
31 Press Release, U.S. Dep't of Justice, Justice Department Recoveries total $1.4 Billion
in Fraud & False Claims in Fiscal Year 2005; more than $15 Billion since 1986 (Nov. 7,
2005), available at http://www.usdoj.gov/opa/pr/2005/November/05 civ 595.html.
32 JACK A. MEYER, FIGHTING MEDICARE FRAUD: MORE BANG FOR THE FEDERAL BUCK 2
(2004), available at www.taf.org/meyerreport.htm.
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a positive return on investment, and billions of dollars in improper
payments yet to be recouped, federal interest in health care fraud is unlikely
to wane any time soon.
B. HARM TO PATIENTS
Given the magnitude of the problem, it is logical that recovery efforts
have focused on the government's role as a defrauded payer. While health
care fraud clearly causes significant financial harm to the federal Treasury,
however, the federal government is not the only-or in some cases even the
primary-victim. Health care fraud also causes significant harm to
patients, be it financial, physical, or less tangible in nature.
1. Financial Injury
Financial injury to patients is perhaps the easiest type of harm to
recognize, in part because it mirrors the government's own economic
injury. Due to the cost-sharing structure of the health care reimbursement
system, fraud often has financial repercussions for patients. Under
Medicare Part B, for example, beneficiaries are responsible for paying 20%
of the Medicare approved charge for covered outpatient services, which
include physician services and drugs administered in a physician's office.33
Under such a cost-sharing mechanism, a fraudulently inflated charge will
result in additional expense to both insurer and patient34-- expense that may
have disproportionately detrimental effects on patients who subsist on
limited incomes, such as many federal program beneficiaries.3 5
These concepts are illustrated by the ongoing controversy over the
prices charged by prescription drug manufacturers. The issue received
widespread public attention in October 2001, when TAP Pharmaceutical
Products agreed to pay $875 million dollars to settle a variety of civil and
criminal fraud allegations stemming from the sale of its cancer drug,
"3 See 42 U.S.C. § 1395i(a) (setting forth 80/20 split for Medicare Part B). This structure
also is common in private insurance. See, e.g., ANNE M. STOLINE & JONATHAN P. WEINER,
THE NEW MEDICAL MARKETPLACE: A PHYSICIAN'S GUIDE TO THE HEALTH CARE SYSTEM IN
THE 1990s, at 62-63 (rev. ed. 1993) (describing co-insurance as a cost-sharing mechanism).
34 Although the pricing mechanisms may be slightly different, similar fraud also occurs
in private insurance. See, e.g., Smith v. United Healthcare Servs., Inc., No. CIV 00-1163
ADM/AJB, 2002 WL 192565 (D. Minn. Feb. 5, 2002) (certifying class in ERISA suit
alleging that insurer overcharged beneficiaries for prescription drug copayments).
35 As Congress recognized while debating the 2003 Medicare reform legislation, "low-
income beneficiaries must often make unacceptable choices between life-saving medicines
and other essentials." H.R. REP. No. 108-391, at 427 (2003) (Conf. Rep.), as reprinted in
2003 U.S.C.C.A.N. 1808, 1810.
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Lupron.36 TAP was alleged to have inflated the prices it reported to the
publications on which Medicare contractors based their "average wholesale
price" ("AWP") calculations for reimbursement purposes, thus assuring that
Medicare payment for Lupron would remain artificially high. By actively
marketing this "spread" between the discounted price paid by physician
customers and the artificially high rate at which Medicare reimbursed the
product, TAP was accused of offering its customers a financial inducement
to prescribe Lupron in violation of the Medicare & Medicaid Anti-
Kickback Statute (and thereby causing customers to submit false claims
under the FCA).37 The allegations involved a substantial amount of money:
A subsequent private suit against the company alleged that while the actual
cost of the drug dropped from $340 to $207 over several years, the
published AWP in fact increased from $418.75 to $623.79.
8
Due to the 20% copayment structure, the Medicare beneficiaries who
took Lupron-patients suffering from cancer, no less-were the direct
victims of this alleged fraud scheme. 39 Because of the widespread use of
AWP as a reimbursement benchmark, the scheme was equally applicable to
patients who purchased the drug through many private insurers. Following
settlement of the federal fraud allegations, a consortium of patients, health
plans, and state attorneys general filed a series of civil actions against the
company for injunctive relief and damages.40 Subsequent investigations
have made clear that the problem is not limited to one pharmaceutical
company, and virtually all of the major drug manufacturers have been sued
for similar activities. 4  At this point, the effect on patients appears
incontestable: The Centers for Medicare & Medicaid Services ("CMS"),
36 See Press Release, U.S. Dep't of Justice, TAP Pharmaceutical Products, Inc. and
Seven Others Charged with Health Care Crimes; Company Agrees to Pay $875 Million to
Settle Charges (Oct. 3, 2001), available at http://www.usdoj.gov/opa/pr/2001/October/
513civ.htm.
17 See id.
38 See In re Lupron(R) Mktg. & Sales Practices Litig., 295 F. Supp. 2d 148 (D. Mass.
2003). As the court noted, "[d]efendants repeatedly assert that ... AWP was a 'sticker
price' and never intended to reflect the drug's true average wholesale price .... There is a
difference between a sticker price and a sucker price." Id. at 168 n.19 (emphasis added).
39 As Congress has noted, "[ijn addition to the financial toll on the U.S. Treasury, these
large spreads also affect Medicare beneficiaries, who are often required to pay dramatically
inflated co-payments for the drugs they receive." H.R. REP. No. 108-39 1, at 583.
40 See In re Lupron(R) Mktg. & Sales Practices Litig., 228 F.R.D. 75 (D. Mass. 2005)
(certifying class and approving final settlement).
41 See, e.g., In re Pharm. Indus. Average Wholesale Price Litig., 230 F.R.D. 61 (D. Mass.
2005) (resolving class certification issues in suit brought by consumers and third-party
payers against pharmaceutical companies); In re Pharm. Indus. Average Wholesale Price
Litig., 307 F. Supp. 2d 196 (D. Mass. 2004) (addressing RICO, antitrust, and consumer
protection allegations brought by employee health plans against pharmaceutical companies).
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which administers the Medicare and Medicaid programs, reported that the
spread for some drugs was so large that the patient's 20% Medicare
copayment was greater than the total price paid by the physician.42 In the
aggregate, OIG has estimated "that if Medicare had paid reimbursements
equal to widely available wholesale prices, beneficiaries would have paid
$175 million less in coinsurance" annually.43 When the effect on privately
insured patients is taken into account, it is clear that the scheme's overall
financial impact on patients was substantial.
2. Physical Injury
Although financial harm may be the easiest form of injury to
recognize, fraudulent activities may also cause physical harm to patients.
As one commentator has noted:
Health care fraud is unique among white collar crimes in its ability to cause physical
harm. This is true for several reasons: (1) often the fraudulent provider is also an
incompetent provider; (2) some types of fraud are also malpractice, such as
performing unnecessary medical procedures to increase billing; and (3) some types of
fraud lead legitimate providers to render poor health care.
4 4
Unlike financial harm, which in fact is the goal of the scheme, physical
injuries tend to be mere byproducts of the fraud. Rather than being
motivated by any malice toward patients, such injury results from the
medical activities (or lack thereof) through which the fraudulent scheme
was carried out.
One way patients may suffer physical injury is when unnecessary
medical procedures are performed solely for the purpose of obtaining
payment from the federal health care programs. A substantial medical
literature has documented the health effects of overtreatment. Even if not
physically harmful in itself, for example, unnecessary diagnostic testing
may lead to "a false positive result [that] may trigger a cascade of
progressively more invasive and expensive tests," with adverse physical
and psychological consequences.45 Similarly, the growing literature on
42 See Medicare Program; Payment Reform for Part B Drugs, 68 Fed. Reg. 50428, 50430
(Aug. 20, 2003) (proposing to revise Medicare drug reimbursement methodology).
43 Id. (emphasis added).
44 Pamela H. Bucy, Crimes By Health Care Providers, 1996 U. ILL. L. REv. 589, 660-61
[hereinafter Bucy, Crimes By Health Care Providers].
45 Peter Franks et al., Gatekeeping Revisited-Protecting Patients from Overtreatment,
327 NEW ENG. J. MED. 424-25 (1992); see also Elliott S. Fisher & H. Gilbert Welch,
Avoiding the Unintended Consequences of Growth in Medical Care: How Might More Be
Worse?, 281 J. AM. MED. Ass'N 446, 449-50 (1999) (noting that harms caused by over-
diagnosis include "labeling" someone who feels well as sick and identification of
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iatrogenic complications in hospital settings-adverse events caused in
some way by the medical intervention itself, including what have come to
be known as "medical errors"--makes clear that such overtreatment is not a
benign phenomenon.46 As one researcher has noted, "More is not better,
and it often is very, very much worse. ' ' 7
If health care is reimbursed on a fee-for-service basis, in which
separate payment is made for each item or service billed, there is a strong
incentive to order unnecessary care.48 These incentives most clearly exist
with regard to minimally invasive tests and other procedures where overuse
is difficult to detect. In one such case, a laboratory provider drew blood for
unnecessary tests despite being aware that the procedures "would provide
no medical or economic benefit (other than to the Lab's bottom line) and
would subject sick patients to needless and intrusive withdrawal of
additional blood, with the attendant (albeit incremental) medical risks., 49
Yet there also are documented instances of providers performing
extremely invasive (and far more lucrative) surgeries on patients who did
not need them. Federal prosecutors recently settled allegations that cardiac
surgeons at Redding Medical Center performed unnecessary heart surgeries
on as many as 700 patients. This included unnecessary open heart and
coronary bypass surgeries, often performed on patients who had already
undergone procedures such as cardiac catheterization or heart valve
replacement. 50 Similarly, in what is "believed to be the first major scam in
"pseudodisease," i.e., "disease that would never become apparent to patients during their
lifetime without the diagnostic test").
46 See, e.g., COMM. ON QUALITY OF HEALTH CARE IN AM., INST. OF MED., To ERR IS
HUMAN: BUILDING A SAFER HEALTH SYSTEM (Linda T. Krohn et al. eds., 2000) (analyzing
magnitude and causes of medical errors); Franks et al., supra note 45, at 425 (noting studies
of hospital-based complications); Chunliu Zhan & Marlene R. Miller, Excess Length of Stay,
Charges, and Mortality Attributable to Medical Injuries During Hospitalization, 290 J. AM.
MED. ASS'N 1868, 1873 (2003) (concluding that "medical injuries in hospitals pose a
significant threat to patients and incur substantial costs to society").
47 Gina Kolata, More May Not Mean Better in Health Care, Studies Find, N.Y. TIMES,
July 21, 2002, § 1, at 1 (quoting Dr. Donald M. Berwick, President of the Institute for
Healthcare Development).
48 See Davies & Jost, supra note 8, at 384 (describing incentives for fraud in fee-for-
service systems).
49 United States ex rel. Kneepkins v. Gambro Healthcare Inc., 115 F. Supp. 2d 35, 42 (D.
Mass. 2000).
50 See Press Release, U.S. Attorney, E. Dist. of Cal., Doctors Accused of Performing
Unnecessary Heart Surgeries at Redding Medical Center Agree to Pay Millions to Settle
Fraud Allegations and Accept Restrictions on Their Medical Practice (Nov. 15, 2005),
available at www.usdoj.gov/usao/cae/PRESS/pdf 2005/11-15-05RMC.pdf, Prosecutors
Reach Overall Settlement of Allegations of Unneeded Cardiac Surgery, 14 HEALTH L. RPTR.
(BNA) 1487 (2005).
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which clinics and surgeons allegedly paid healthy patients to actually
undergo invasive and risky procedures," several Blue Cross and Blue Shield
plans filed suit in March 2005 against a number of Southern California
outpatient surgery clinics, alleging a massive "Rent-a-Patient" scheme in
which healthy individuals were recruited to travel to the surgery centers for
procedures such as colonoscopies and endoscopies.51
Harm may also occur when medically necessary care is performed in
an improper manner in order to maximize reimbursement. In United States
v. Laughlin, for example, an obstetrician-gynecologist was convicted of
multiple counts of Medicaid fraud and mail fraud.52 In one case the
physician performed a tubal ligation four weeks after delivering a patient's
baby by caesarian-a tactic that permitted him to bill for two surgeries
rather than one, which would have been the case had he performed the tubal
ligation at the same time as the original procedure.53 Unfortunately,
undergoing a second surgery in the same anatomical area so soon after the
first also posed a risk of serious harm to the patient.54
Even if the unnecessary or ill-timed services do not in themselves pose
any risk to patients, courts have recognized that harm may occur if patients
rely on these useless treatments to delay seeking legitimate care. In United
States v. Vivit, a physician was convicted of mail fraud based on the
provision of unnecessary services, including physical therapy ultrasound
and electrical muscle stimulation performed by unlicensed office
personnel.55 Acknowledging that patients had relied on the physician to
treat their medical conditions, the court noted, "[b]y failing to examine such
patients properly, Vivit created a risk that, had these patients suffered
serious injuries, their injuries would remain untreated., 56 In some cases, the
false reliance also endangers third parties. A scheme involving the sale of
fraudulent HIV kits, for example, was found to "pose[] a substantial threat
to public health because [the defendant] purported to provide reliable HIV
51 Blue Cross and Blue Shield Plans File $30 Million Lawsuit Alleging Rent-A-Patient
Fraud in Southern California, BCBSHEALTHISSUES.COM, Mar. 11, 2004,
http://bcbshealthissues.com/proactive/newsroom/release.vtml?id=152284; Jonathan D.
Glater, In a Surgery Capital, a Swirl of Fraud Charges, N.Y. TIMES, July 10, 2005, § 3, at 1
(describing the allegations and some of the "patients").
52 26 F.3d 1523 (10th Cir. 1994).
" Id. at 1530.
14 Id. at 1530-31.
" 214 F.3d 908 (7th Cir. 2000). The case also involved more straightforward allegations
of billing fraud, including bills submitted for ultrasound therapy a year before the equipment
was delivered to the physician's office. Id. at 912.
56 Id. at 922; see also United States v. Bachynsky, 949 F.2d 722, 735 (5th Cir. 1991)
("[W]hile relying on Dr. Bachynsky's ineffective course of treatment, his patients may have
been foregoing more effective, safer, and legitimate treatments elsewhere.").
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screening when in fact there was no scientific basis for the test 'results' he
sent to customers," leading to at least one customer "who unwittingly put a
new partner at risk.,
57
Moreover, while overtreatment is the hallmark of fraud in a fee-for-
service reimbursement system, the incentives are quite different when
payment is made on a lump-sum basis-as under the Medicare inpatient
prospective payment system, or in capitated forms of managed care. Where
reimbursement is limited to a predetermined amount, the temptation may be
to "inappropriately deny necessary care or provide substandard care, thus
defrauding and abusing consumers, purchasers, and intermediaries." 58 One
area of particular interest has been the quality of care provided to
beneficiaries in health care institutions, such as nursing homes and
hospitals. Since the mid-1990's, the federal government has investigated
allegations that understaffed nursing facilities pose serious threats to patient
health, thus resulting in fraudulent bills for care.59 Although the nursing
facilities have not admitted any liability in these proceedings, common
elements of the settlements include the payment of civil penalties, the
development of specific training and oversight procedures for problem
areas, quality monitoring by outside entities, and the adoption of a corporate
compliance program.60 More recently, the Washington Post ran a series of
stories on continuing quality problems in Medicare hospitals, profiling not
only Redding Medical Center but also Palm Beach Gardens Medical
Center, whose heart surgery unit was long-perceived as "a breeding ground
for germs., 61 In other cases, the fraud scheme results in a combination of
57 United States v. Greene, 17 F. App'x 722, 724 (9th Cir. 2001).
58 Davies & Jost, supra note 8, at 385-86 (describing potential fraud in managed care).
59 See, e.g., United States v. NHC Health Care Corp., 163 F. Supp. 2d 1051, 1056 (W.D.
Mo. 2001) ("At some very blurry point, a provider of care can cease to maintain this
standard by failing to perform the minimum necessary care activities required to promote the
patient's quality of life. When the provider reaches that point, and still presents claims for
reimbursement to Medicare, the provider has simply committed fraud against the United
States."); David R. Hoffman, The Role of the Federal Government in Ensuring Quality of
Care in Long-Term Care Facilities, 6 ANNALS HEALTH L. 147 (1997) (describing patient
injuries that gave rise to nursing home settlement).
60 See Hoffman, supra note 59, at 154-55 (explaining terms of settlement); Consent
Order and Judgment, United States v. Chester Care Ctr., No. 98-CV-139 (E.D. Pa. Jan.
1998), available at http://www.usdoj.gov/usao/pae/nursing/chester3.pdf (describing terms of
settlement).
61 Gilbert M. Gaul, Inefficient Spending Plagues Medicare: Quality Often Loses Out as
40-Year-Old Program Struggles to Monitor Hospitals, Oversee Patients, WASH. POST, July
24, 2005, at Al ("[Long-standing problems at Palm Beach Gardens included:] Dust and dirt
covered some surgical equipment. Trash cans and soiled linens were stored in hallways. IV
pumps were spattered with dried blood. One patient's wife said she saw a medical assistant
tear surgical tape with his teeth."); Gilbert M. Gaul, At California Hospital, Red Flags and
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over-, under-, and improper treatment. United States v. Talbott, for
example, involved allegations "that root canal procedures were performed
on teeth that should have been extracted as well as on healthy teeth; that
some procedures billed as root canals were at best pulpotomies, and that in
certain instances teeth were filled for no apparent reason while obvious
cavities went undetected. 62 From these examples, it is clear that fraudulent
activities may cause physical injuries to patients in a variety of ways.
3. Intangible Harm
In addition to financial and physical harm, patients can be injured by
health care fraud in less tangible ways. One of the key commodities of the
health care system is information, specifically patient information. At core,
information constitutes the sum total of the record of our individual health
histories-information that will be used not only as the basis for future
treatment decisions, but also for purposes as varied as insurance
underwriting and job applications. Professor Peter Jacobson explains:
"Health care is a flashpoint for the debate over privacy because of the
inherent sensitivity of our medical records. Used properly, medical records
can be disclosed for life-saving purposes. Used improperly, the results can
be very damaging to one's reputation or ability to seek employment.,
63
From the perspective of those tempted to commit health care fraud,
however, information performs a more crass function: it is also the basis on
which health care is reimbursed. In short, bills are paid only if they list
specific services performed for identifiable patients. This creates incentives
for the fraudulent use of health care information, and explains why
Congress considered the protection of such information to be a federal
priority.64
Intangible harm may arise when a health care provider misuses patient
information to obtain reimbursement for services that were not performed-
a traditional form of health care false claim.65 In United States v. Sidhu, for
example, a physician billed the federal health care programs for
an FBI Raid: State Regulators Cited Concerns But Say They Couldn 't Force Change, WASH.
POST, July 25, 2005, at A9 (describing problems at Redding Medical Center).
62 590 F.2d 192, 194 (6th Cir. 1978) (affirming convictions of dentists).
63 Peter D. Jacobson, Medical Records and HIPAA: Is It Too Late To Protect Privacy?,
86 MiNN. L. REV. 1497, 1497 (2002).
64 See HIPAA, Pub. L. No. 104-19 1, 110 Stat. 1935, 2021-34 (1996) (enacting privacy
and security protections); 45 C.F.R. §§ 160.101-164.534 (2005) (setting forth privacy
regulations).
65 See, e.g., Peterson v. Weinberger, 508 F.2d 45, 47-48 (5th Cir. 1975) (imposing




biofeedback services, despite the fact that patients "never saw [the]
biofeedback machine, and [the provider] generally just talked to the patient,
performing more of a counseling role."66  In some cases the provider
renders legitimate services to the patient, but also submits bills for
additional services the patient did not receive. That was the case in Del
Mazo v. Sanchez, where a physician who treated a mother also billed
Medicaid for the treatment of her five children, whom he had never seen.6 7
In other cases, the goal of the scheme is to permit the provider to generate
bills without any patient interaction at all-such as where patient
information is stolen or where bills are generated in the names of deceased
68patients.
When Medicare is billed for services allegedly rendered to nonexistent
or deceased patients, the primary harm is to the federal Treasury. Where
fraudulent bills are generated in the name of a living patient, on the other
hand, they may interfere with the patient's ability to obtain medical services
in the future. As Professor Pamela Bucy notes, part of that concern is
clinical: "If a fraudulent provider falsifies a patient's diagnosis or
misrepresents medical services that were provided so as to increase billings,
the patient's file may contain false information. Subsequent providers
relying on such information may unknowingly render inadequate or
inappropriate medical care."69  And even where fraudulent bills do not
affect future treatment, they may implicate future coverage. Because most
insurance benefits have annual or lifetime limits, the submission of
fraudulent bills in a patient's name may mean that little or no coverage will
70be available when the patient legitimately requires care. In one reported
66 130 F.3d 644, 648 (5th Cir. 1997).
67 366 S.E.2d 333, 335 (Ga. Ct. App. 1988).
68 See U.S. GEN. ACCOUNTING OFFICE, HEALTH CARE FRAUD: SCHEMES COMMITTED BY
CAREER CRIMINALS AND ORGANIZED CRIMINAL GROUPS AND IMPACT ON CONSUMERS AND
LEGITIMATE HEALTH CARE PROVIDERS 8-9 (1999) [hereinafter GAO, HEALTH CARE FRAUD]
(noting fraudulent use of beneficiary information that was stolen, illegally purchased, or
otherwise obtained); see also Sidhu, 130 F.3d at 647 (accusing physician of billing for
psychotherapy on dates when he was out of town and, in one case, for "a patient who was no
longer living"). Note that an enterprising criminal could also obtain payment by fraudulently
submitting bills in the name of a provider. See, e.g., Oregon Medical Association, Medicare
Fraud Alert, OMA ONLINE, Jan. 7, 2005 (on file with author) (warning physicians of
individuals who are obtaining provider information by misrepresenting themselves as
Medicare employees).
69 Bucy, Crimes By Health Care Providers, supra note 44, at 661; see also GAO,
HEALTH CARE FRAUD, supra note 68, at 4 (noting that "false medical histories for some
beneficiaries could affect the care prescribed, as the care could be based on false data").
70 See, e.g., 42 U.S.C. § 1395d(a) (2000) (limiting Medicare Part A coverage of inpatient
hospital services is limited to 90 days per spell of illness plus 60 lifetime reserve days, and
skilled nursing care to 100 days per spell of illness).
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case, a psychiatrist was accused of submitting false bills for daily therapy
for hospitalized patients. 7' The court noted:
[Patients] were often admitted to the hospital needlessly or their stays in the hospital
were extended beyond what was necessary and their insurance companies were billed
for treatment not given. Further, the patients' treatment benefits were often exhausted
by the time of their discharge. In some cases, patient benefits were exhausted for a
life-time; therefore, any future treatment needs would not be covered under their
current policy.
72
Thus, even if it has no immediate physical or financial effect, the use of
fraudulent information has the potential to cause significant harm to
patients in the future.
In addition, some fraudulent schemes interfere with patient autonomy
by coercing patients into making certain care choices. In one particularly
egregious Anti-Kickback case, the head of a chemical dependency program
for pregnant women paid illegal remuneration to obtain referrals of patients
from a federally-funded drug abuse treatment research program.73 More
disturbing than the obvious payment for referrals was the fact that the
illegal arrangement directly interfered with the counseling the women
received: at trial, several women testified that they had been threatened with
the loss of their children if they did not opt to receive treatment from this
specific chemical dependency program.74  Although such "dignitary"
affronts to autonomy are notoriously difficult to compensate under the tort
system, they nonetheless constitute a relevant form of harm for the purposes
of this inquiry.75
II. BARRIERS TO RECOGNITION OF PATIENT HARM IN FRAUD RECOVERY
Despite evidence that health care fraud harms patients, patient
compensation has not been a priority of enforcement efforts to date. There
are many reasons for this oversight. The failure to make patient
compensation an integral component of fraud recovery is due, in large part,
to limitations on the uses that can be made of recovered funds under current
71 United States v. Burgos, 137 F.3d 841 (5th Cir. 1998).
72 Id. at 844; see also GAO, HEALTH CARE FRAuD, supra note 68, at 4 (concluding that
beneficiaries "unknowingly risk exhaustion of their insurance benefits, due to false
information included in the claims that use their names").
73 United States v. Starks, 157 F.3d 833 (1 1th Cir. 1998).
14 Id. at 837.
75 See, e.g., Alan Meisel, A "Dignitary" Tort as a Bridge Between the Idea of Informed
Consent and the Law of Informed Consent, 16 J.L. MED. & HEALTHCARE 210 (1988)
(discussing how dignitary injuries have not adequately been addressed by informed consent
law); Richard S. Saver, Medical Research and Intangible Harm, 74 C1NN. L. REV.
(forthcoming 2006) (discussing intangible harm in medical research context).
2006]
JOAN H. KRA USE
federal law. Other reasons are more practical in nature: the emphasis on
governmental recovery is consonant with the government's goals in
pursuing fraud cases, and such recoveries do in fact benefit the patient
population (albeit indirectly). Finally, the assumptions underlying the white
collar crime framework may well be a contributing factor.
A. WHERE DO HEALTH CARE FRAUD RECOVERIES GO?
Despite the influx of dollars from successful fraud enforcement,
current law provides few avenues for these funds to be allocated directly to
injured beneficiaries. The disposition of federal health care fraud
recoveries is governed by HIPAA.7 6 In a civil false claims case, for
example, a portion of the proceeds (usually 15-30%) will be awarded to any
qui tam relator(s) who initiated the suit.7 7 Most of the remaining funds-as
well as those recovered from civil monetary penalties, other civil
assessments, and criminal fines and forfeitures 78-are deposited into the
perennially near-insolvent Medicare Part A Trust Fund.79 Under the
HIPAA Fraud and Abuse Control Program provisions, however, this money
is available for appropriation back to the Health Care Fraud and Abuse
Control Account, a special expenditure account created to fund DOJ and
OIG health care anti-fraud efforts.8 0 Appropriations are controlled by the
Secretary of HHS and the Attorney General, who jointly certify the
amounts necessary to fund anti-fraud programs each year within broad
ranges established by Congress.8 ' In loose terms, a portion of the money
recovered through federal fraud prosecutions and settlements is available-
at the discretion of the agencies themselves-for appropriation back to DOJ
and HHS.
76 Pub. L. No. 104-191, 110 Stat. 1936 (1996).
" See 31 U.S.C. § 3730(d) (2000) (discussing the range of awards for qui tam plaintiffs);
42 U.S.C. § 1395i(k)(2)(C)(iv) (2000) (exempting funds awarded to relator from amounts
allocated to Trust Fund under HIPAA).
78 See 42 U.S.C. § 1395i(k)(2)(C) (setting forth rules for deposits).
79 See id. § 1395i(k)(2)(C)(iv) (authorizing the transfer of penalties and damages
obtained in health care FCA cases to the Trust Fund, with the exception of funds awarded to
a relator, funds designated for restitution, or as otherwise authorized by law).
so See id. § 1395i(k)(3) (describing appropriations to the Health Care Fraud and Abuse
Control Account).
8" See id. § 1395i(k)(3)(A)(i) (setting out the maximum amounts available to HHS and
DOJ). In FY 2004, the Secretary and the Attorney General certified $240 million as
necessary for health care anti-fraud efforts; HHS received approximately $191 million, and
DOJ received approximately $49 million. Id.; see DEP'T OF HEALTH & HUMAN SERVS. &
DEP'T OF JUSTICE, HEALTH CARE FRAUD AND ABUSE CONTROL PROGRAM ANNUAL REPORT
FOR FY 2004, at 4 (2005), available at http://www.oig.hhs.gov/publications/docs/hcfac/
hcfacreport2004.htm.
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This funding structure suggests that HIPAA may have created a
"bounty system," albeit an attenuated one. 2 To be sure, the very nature of
law enforcement provides incentives for prosecutors to be successful, just
as an annual appropriations process puts a premium on agencies
demonstrating that Congress gets what it pays for. Indeed, DOJ has long
had a "3% fund," under which money from civil recoveries is deposited in a
special fund that supports other civil enforcement actions. 83 Nonetheless,
there is a fear that HIPAA may have tied future funding too closely to past
success. Just as critics have warned that the FCA qui tam provisions create
incentives for relators to file meritless suits in the hopes of reaping financial
windfalls,8 4 critics fear that the motivations of OIG and DOJ personnel will
be tainted by a structure that permits them to receive a financial boost with
each successful prosecution.85  In light of long-standing concerns about
overzealous health care fraud enforcement, these new developments are
decidedly unwelcome.86 Nor are these concerns simply academic. Within
the health care provider community, the Control Account mechanism is
derided as
a self-perpetuating enforcement scheme .... Rewarding those who enforce Medicare
fraud and abuse regulations with more program funds creates strong institutional
incentives for those enforcers to pursue as many investigations and fraud and abuse
82 See, e.g., Roger Feldman, An Economic Explanation for Fraud and Abuse in Public
Medical Care Programs, 30 J. LEG. STUD. 569, 574 (2001) ("Although this is not a pure
bounty system, it is much closer than had previously been the case."). The effect is further
attenuated by the fact that appropriations are capped. See 42 U.S.C. § 1395i(k)(3)(A)(i)(lII)
(capping appropriations at FY 2003 levels).
83 See, e.g., Civil Division, http://www.usdoj.gov/usao/okn/civil.html (last visited Mar. 7,
2006) (describing the Affirmative Civil Enforcement ("ACE") program in the U.S.
Attorneys Office for the Northern District of Oklahoma).
84 As the Supreme Court cynically has concluded, "qui tam relators are ... motivated
primarily by prospects of monetary reward rather than the public good." Hughes Aircraft
Co. v. United States ex rel. Schumer, 520 U.S. 939, 948 (1997).
85 Professor Dayna Matthew argues that while "[p]ublic prosecutors do not have a direct
personal interest in funds deposited into the Control Account from their prosecutorial efforts
... they do have an interest in the size of the Control Account as a measure of their
professional success and as a source of financing for future professional endeavors." Dayna
Bowen Matthew, Tainted Prosecution of Tainted Claims: The Law, Economics, and Ethics
of Fighting Medical Fraud Under the Civil False Claims Act, 76 IND. L.J. 525, 580 n.319
(2001); see also id. at 580 (noting that "[ijronically, these financial incentives arguably pose
the same threat to prosecutorial discretion, as prosecutors claim self-referral fees pose to
providers' medical judgment").
86 See, e.g., Joan H. Krause, "Promises to Keep": Health Care Providers and the Civil
False Claims Act, 23 CARDozo L. REv. 1363, 1412-13 (2002) [hereinafter Krause,
"Promises to Keep "] (discussing complaints of prosecutorial overreaching in health care
fraud cases).
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prosecutions as possible thus increasing the risk that the innocent as well as the guilty
will suffer punishment.i
The criticism has been vocal enough to put the government on the
defensive: vehemently denying the existence of a bounty system, Medicare
publications tout the fact that "[a]ll recovered monies are returned to the
Medicare Trust Funds" and seek to assure the public that HIPAA-mandated
enforcement activities have "a stable source of funding under" the law.
88
The Control Account is by no means the first productivity-based
funding structure that has been alleged to taint the discretion of prosecutors
and law enforcement personnel. Virtually identical allegations have been
levied against the forfeiture provisions that, since the 1970's, have
supported the nation's so-called "War on Drugs.,8 9 Similar to the Control
Account, federal law has permitted forfeited assets to be placed into a
special DOJ Assets Forfeiture Fund, rather than deposited into the general
federal Treasury. 90 This money, in turn, is available to the Attorney
General to fund a variety of law enforcement activities, including
reimbursement of forfeiture-related expenses by federal, state, and local
agencies. 91 According to Professors Eric Blumenson and Eva Nilsen, who
have made a detailed study of expenditures and enforcement priorities
under this program, these provisions "have not simply enhanced the ability
of law enforcement to do its job, but rather have changed the nature of the
job itself."92 Blumenson and Nilsen describe two primary objections to the
self-funding nature of the law: (1) the conflict of interest between
"legitimate law enforcement goals" and initiatives that "maximize funding
87 Emord, supra note 17, at 32; see also Hyman, supra note 16, at 158 ("To be sure,
CMS does not get to 'eat what it kills.' . . . Although this structure prevents the
government's fraud control system from operating on a pure bounty system, there is still
considerable suspicion in the provider community on this point.").
88 HEALTH CARE FIN. ADMIN., U.S. DEP'T OF HEALTH & HUMAN SERVS., THE MEDICARE
INTEGRITY PROGRAM: PAY IT RIGHT! 1, 11 (2001); see also Hyman, supra note 16, at 158
(noting that CMS publications "go out of their way to label [the bounty allegation] a
'common misperception').
89 See Eric Blumenson & Eva Nilsen, Policing for Profit: The Drug War's Hidden
Economic Agenda, 65 U. CHI. L. REV. 35 (1998).
90 28 U.S.C. § 524(c)(1) (2000); Blumenson & Nilsen, supra note 89, at 50-51
(describing funding mechanism).
91 28 U.S.C. § 524(c)(1)(A) (describing allowable use of funds). Even if the case is a
federal one, state and local law enforcement agencies are permitted to receive funding "that
bears a reasonable relationship to the degree of direct participation . . .and will serve to
encourage further cooperation between" the agencies. 21 U.S.C. § 881(e)(3)(A)-(B) (2000);
see also Blumenson & Nilsen, supra note 89, at 50-51 (describing effect of the "equitable
sharing program," which directs a significant portion of seized assets to state and local law
enforcement).
92 Blumenson & Nilsen, supra note 89, at 56.
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for their operations," 93 and (2) the loss of accountability that occurs when
agencies are able to self-fund rather than going through the normal
legislative appropriations process. 94 The result, in their view, is a Drug War
that has become self-perpetuating not so much due to the political urgency
of its objective, but rather because of the hidden bureaucratic financial
incentives.95
While there is little empirical research on the topic, the first of these
concerns-that the promise of self-funding can skew law enforcement
priorities-is a distinct possibility in the health care fraud context. As the
Author has argued elsewhere, the vague contours of the fraud laws leave
prosecutors with enormous discretion over which activities to target.96 The
process is complicated by the specter of enormous FCA penalties and the
threat of exclusion from federal health care programs, which give health
care providers strong incentives to settle fraud allegations rather than
pursuing the litigation through trial.97 In fact, the potential for skewing
priorities may be greater in health care fraud cases than in the drug context,
where the prohibitions appear relatively clear (albeit draconian). Because
of significant ambiguity in the regulations governing participation in the
federal health care programs, however-what Professor James Blumstein
has described as regulatory "gray area[s]" rather than "raw fraud ' 98 -
prosecutors have a great deal of discretion over whether to pursue
questionable activities as fraud or to permit them to be resolved through
HHS administrative channels. This discretion, in turn, raises the possibility
that prosecutors may use the litigation process as a means to resolve such
regulatory ambiguities. 99 Indeed, to the extent federal prosecutors benefit
financially from fraud settlements involving gray areas, but do not similarly
benefit if HHS personnel address the same behavior by clarifying federal
health care program rules, the Control Account mechanism provides yet
93 Id.
94 Id. at 84-100 (noting both separation of powers and policy objections).
95 Id. at 39-40. Blumenson and Nilsen note that the self-perpetuating nature of these law
enforcement activities is particularly ironic in light of the failure to achieve any meaningful
improvement in drug usage. Id. at 37-39.
96 For a discussion of prosecutorial discretion in the context of health care fraud, see
Krause, "Promises to Keep, "supra note 86, at 1410-15.
97 Id.
98 James F. Blumstein, What Precisely is "Fraud" in the Health Care Industry?, WALL
ST. J., Dee. 8, 1997, at A25.
99 See Krause, A Conceptual Model, supra note 8, at 110-32 (describing examples of the
use of litigation to fill regulatory gaps, and the problems inherent in such an approach).
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another motive for pursuing much maligned forms of "regulation by
litigation."'
00
In the health care fraud context, Blumenson and Nilsen's non-
accountability concerns may be mitigated by the fact that Congress
established upper limits on the amount that may be appropriated to the
Control Account, and required the Attorney General and Secretary of HHS
to submit a joint annual report accounting for their expenditures. 1 While
subject to some degree of oversight, however, the Control Account
mechanism still permits HHS and DOJ to favor fraud enforcement over
other health care funding needs. Because the funds certified for inclusion in
the Control Account are transferred from the Medicare Part A Trust Fund,
they are not available to be spent on patient care or other efficiency-
enhancing administrative program activities 102  This is analogous to
problems noted by Blumenson and Nilsen, who note that forfeited assets
that are siphoned off for law enforcement purposes are no longer available
for public funding of proactive drug treatment and education programs.103
Yet this logic is also somewhat circular: without the Control Account
mechanism, Congress would be required to fund all fraud enforcement
activities directly in addition to funding the Medicare program, all from the
same finite pool of resources. 0 4 Moreover, such criticism is belied by the
1oo See Joan H. Krause, Regulating, Guiding, and Enforcing Health Care Fraud, 60
N.Y.U. ANN. SuRv. AM. L. 241, 272-74 (2004) [hereinafter Krause, Regulating, Guiding,
and Enforcing] (describing dangers of "regulation by litigation" in the health care fraud
context). Whether these incentives rise to the level of illegality is unclear. In 1980, the
Supreme Court held that a provision of the Fair Labor Standards Act that returned civil
penalties from child labor violations to the Department of Labor, rather than the federal
Treasury, did not violate the Due Process Clause because the possibility of prosecutorial bias
was remote. Marshall v. Jerrico, Inc., 446 U.S. 238 (1980). In particular, the Court noted
that no individual stood to benefit from overzealous collection efforts, the civil penalties
accounted for a small percentage of the agency's budget, and the distribution mechanism
functioned in a non-biased way. Id. at 250-51. Application of these factors to the Control
Account requires an analysis of data that is beyond the scope of this Article. Cf Blumenson
& Nilsen, supra note 89, at 62-66 (arguing that an analysis of these factors in the drug
forfeiture context suggests the funding scheme is unconstitutional).
"'1 See 42 U.S.C. § 1395i(k)(3) (2000) (setting caps); id. § 1395i(k)(5) (requiring annual
report). But see 28 U.S.C. § 524(c)(6) (2000) (requiring Attorney General similarly to
transmit reports to Congress regarding the Asset Forfeiture Fund).
102 42 U.S.C. § 1395i(k) (explaining funding transfer mechanism). As one critic notes,
"[b]ecause funds extorted from physicians will not be used to cover Medicare program costs
but to extort more funds, Congress will not be able to disguise cost increases in Medicare."
Emord, supra note 18, at 32.
103 See Blumenson & Nilsen, supra note 89, at 82.
104 As one House Report on the HIPAA legislation noted, "[c]urrently, Medicare's
program integrity functions are subsumed under Medicare's general administrative budget."
H.R. REP. No. 104-496 pt. 1, at 79 (1996).
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fact that the amount collected in fraud prosecutions-and hence returned to
the Trust Fund-far exceeds the amount transferred back to the Control
Account.'0 5 While it is possible to argue that any removal of Trust Fund
monies is ill-advised, the net effect of this investment strategy appears to be
a positive one.
Although the precise nature of prosecutors' stake in health care fraud
settlements may not be critical to the debate over patient-centered recovery,
it nonetheless raises concerns. For our purposes, what is clear is that the
funds recovered from health care fraud enforcement go to the Medicare
Trust Fund, to the Control Account, to any relators who initiated the
litigation, and to the federal agencies that investigate and prosecute health
care fraud-but not directly to remedy the harm suffered by the patients in
whose names these investigations are mounted. Combined with the
practical considerations underlying the government's approach to these
cases and the traditional posture of white collar crime enforcement, these
funding rules help to explain why patient compensation has been
disfavored, or at the very least overlooked.
B. RECOGNITION OF PATIENT HARM UNDER CURRENT LAW
The laws governing health care fraud and abuse recognize the potential
for patient harm as relevant both to the imposition and to the amount of
sanctions. A prime example is the "health care fraud" crime enacted by
HIPAA, which imposes progressively longer terms of imprisonment on
those who defraud a health care benefit program depending on the level of
physical harm caused-ranging from a base term of no more than 10 years
in prison, to no more than twenty years if the activity "results in serious
bodily injury," to "any term of years or for life" if death results. 0 6
Similarly, in determining the length of a provider's mandatory exclusion
from federal health care programs, the fact that the prohibited acts "had a
significant adverse physical, mental, or financial impact on one or more
program beneficiaries or other individuals" is an aggravating factor
weighing in favor of more lengthy exclusion.10 7  When calculating the
amount of civil monetary penalties to be imposed, the fact that "false or
105 See MEYER, supra note 32, at 5 (noting that an estimated $1.4 billion was returned to
the Trust Fund in FY 2002, while only $209 million was transferred to the Control Account).
106 18 U.S.C. § 1347 (2000).
107 42 C.F.R. § 1001.102(b)(3) (2005); see also id. § 1001.801(c)(2)(iii) (noting that
where managed care organization fails to furnish medically necessary items and services,
fact that such denial "had or could have had a serious adverse effect" is relevant to length of
exclusion). Similarly, in determining the appropriate length of permissive exclusions,
aggravating factors include the fact that the actions "had a significant financial impact on
program beneficiaries or other individuals." Id. § 1001.20 1(b)(2)(i).
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misleading information given resulted in harm to the patient, a premature
discharge or a need for additional services or subsequent hospital
admission" similarly is an aggravating circumstance warranting higher
penalties. 08 In addition, physicians who knowingly and willfully bill
Medicare patients for excessive charges are subject to civil monetary
penalties,'0 9 as are managed care organizations that impose excessive
premiums on their enrollees. 10 It is clear, then, that the federal laws and
regulations governing health care fraud acknowledge physical and financial
harm to patients as factors relevant to both the necessity and severity of
sanctions. The fact that such harm is relevant, however, does not mean that
it will be remedied separate from the government's own injury.
As a practical matter, part of the reason patient compensation is not a
more significant aspect of health care fraud recovery is that the
government's motivations for pursuing fraud enforcement are dual in nature
and dependent on the factual context in which the fraud occurs. In schemes
involving the misappropriation of patient information for the purposes of
generating false bills, for example, the harm to the patient is largely
incidental to the fraud on the government payer: the fraud occurs when the
bill is submitted, regardless of whether the patient has suffered any injury.
Other schemes, however, operate in the reverse: the fraud can only occur
after the patient is harmed. If a nursing home mistreats a resident, for
example, the harm to that patient is complete; in contrast, fraud will not
occur until the institution submits a bill for the services (and only then,
most likely, if the allegations are extensive and systemic)."'
In essence, then, the federal government's interest in the former
category of cases emanates from its role as a defrauded payer, and in the
latter category from its authority to protect vulnerable individuals."
2
Demanding that the federal government be more creative in disbursing the
10' Id. § 1003.106(b)(1)(iv).
109 See 42 U.S.C. § 1395u(j)(1)(A) (2000) (stating prohibition); id. § 1395u(j)(2) (setting
forth exclusion and CMP authorities).
'10 See id. § 1395mm(i)(6) (stating prohibition and listing penalties).
11 See, e.g., United States v. NHC Healthcare Corp., 163 F. Supp. 2d 1051, 1055 (W.D.
Mo. 2001) (noting that "Defendants are not being sued simply for violating the standard of
care .... [r]ather, Defendants are being sued because they allegedly failed to provide the
services that they billed for"); id. at 1055 n.3 (distinguishing malpractice from FCA
liability).
112 Unlike the states, the federal government does not have an explicit "police power" to
protect the health of citizens; instead, the federal government's authority to regulate public
health is derived from specific powers enumerated in the Constitution, such as the powers to
tax, spend, and regulate interstate commerce. See LAWRENCE 0. GOSTIN, PUBLIC HEALTH
LAW: POWER, DUTY, RESTRAINT 34-55 (2000) (analyzing state and federal public health
authorities).
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money recovered from health care fraud investigations may conflate these
roles. As Professor William Sage has noted, "[a] central, unresolved
question is whether the principal purpose of fraud and abuse law is to
protect financial integrity or patient welfare."113  In both situations, the
tendency to overlook patient compensation is based on a concern for
diverting recovered funds from their respective primary purposes. Where
the federal health care programs are defrauded, the primary goal is to
remedy the government's own harm. Recovered funds are directed to the
Medicare Trust Fund because it is the Trust Fund that improperly paid for
these services; sharing the recovery with individual patients, while a
laudable goal, would have the effect of siphoning scarce program resources
away from the program. 14 Thus, the focus on health care fraud in these
cases is largely one of program integrity and solvency, rather than an
attempt to invoke a general police power to assure the quality of the
country's medical care. By contrast, where the government is primarily
acting in its role as protector, its goals are more in line with the traditional
deterrent purposes of criminal law: "to prevent harm to society...
accomplishe[d] by punishing those who have done harm and by threatening
with punishment those who would do harm, to others."" 5 But channeling
recovered money to patients, at least in significant amounts, would drain the
resources needed to fund such public welfare enforcement and might be
perceived as weakening the deterrent force of the law.16
"13 William M. Sage, Fraud andAbuse Law, 282 J. AM. MED. Ass'N 1179, 1180 (1999).
H4 See supra Part IL.A (describing disposition of federal health care fraud recoveries).
115 WAYNE R. LAFAVE, CRIMINAL LAW § 1.2(e) (4th ed. 2003).
116 One could argue, by analogy, to the analysis done in cases in which a portion of the
recovery is diverted to a qui tam relator or private attorney general. See, e.g., John C.
Coffee, Jr., Rescuing the Private Attorney General: Why the Model of the Lawyer as Bounty
Hunter is Not Working, 42 MD. L. REV. 215, 246 (1983) (arguing that nonpecuniary
settlements, which have become common in such cases, threaten deterrence more than
victim compensation); Marsha J. Ferziger & Daniel G. Currell, Snitching for Dollars: The
Economics and Public Policy of Federal Civil Bounty Programs, 1999 U. ILL. L. REV. 1141,
1152 (noting that "higher bounties would decrease revenues in each individual case because
of the higher bounty cost"); Jill E. Fisch, Class Action Reform, Qui Tam, and the Role of the
Plaintiff 60 LAW & CONTEMP. PROBS. 167, 201 (1997) (arguing in favor of a hybrid qui
tam/class action remedy in which "the government would sacrifice its current monetary
recovery in enforcement actions in favor of compensation for injured victims"); cf Geoffrey
P. Miller & Lori S. Singer, Nonpecuniary Class Action Settlements, 60 LAW & CONTEMP.
PROBS. 97, 113 (1997) (arguing that non-monetary class action settlements serve the goal of
deterrence to the extent they force "the defendant [to] internalize the costs of harm"); David
Rosenberg, Decoupling Deterrence and Compensation Functions in Mass Tort Class Actions
for Future Loss, 88 VA. L. REV. 1871, 1892 (2002) (noting that "[h]ow damages are
distributed among plaintiffs ... is generally.., irrelevant to achieving deterrence").
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Lest this Article overstate the case, however, it is important to note
that patients do, in fact, benefit from general fraud recoveries-both in
terms of the quality and the security of their health care benefits.1 17 When
nursing homes or hospitals settle quality-related fraud allegations, for
example, the settlement agreement is likely to include provisions directly
related to improving the quality of the care rendered-such as specialized
training, monitoring and quality assessment, and mandated reporting to the
U.S. Attorney's Office. 1 8  While such provisions may not compensate
patients who have suffered harm in the past, they should improve the
quality of care provided to facility residents in the future. Moreover, health
care fraud recoveries play a role in extending the solvency of the Medicare
Trust Fund, which in turn permits the program to provide services to
present and future beneficiaries.1 19 By reclaiming diverted program funds,
health care fraud enforcement increases the likelihood that the Medicare
program will be able to provide care for the ever-growing beneficiary
population (a benefit as well to the future generations of taxpayers who may
be called upon to shoulder an increasing portion of the program's finances).
Once again, however, the protection of beneficiary entitlement in the
aggregate is not the same thing as compensating individuals who personally
have been harmed by fraudulent activities.
A few anti-fraud provisions do provide for a return of money directly
to injured patients. For example, under current law physicians who do not
participate in the Medicare program cannot charge Medicare patients more
than 115% of the Medicare-approved charge. 20 A physician who violates
this provision is subject to exclusion and/or civil monetary penalties, and
117 Nor are patients without options if the federal government declines to engage in more
creative efforts to disburse fraud recoveries; a variety of mechanisms exist at the state level
to redress direct patient harm, most notably the tort system. See, e.g., W. PAGE KEETON ET
AL., PROSSER AND KEETON ON THE LAW OF TORTS § 1, at 5-6 (5th ed. 1984) (describing tort
law as "a body of law which is directed toward the compensation of individuals, rather than
the public, for losses which they have suffered within the scope of their legally recognized
interests").
118 See Hoffman, supra note 60, at 154-55 (describing settlement in United States v. GMS
Management-Tucker, Inc., No. 96-1271 (E.D. Pa. Feb. 21, 1996)); Press Release, U.S.
Attorney's Office, U.S. Attorney's Office Reaches Agreement with Hospital to Resolve
Failure of Care Allegations Stemming From Improper Use of Patient Restraints (July 25,
2005) available at www.usdoj.gov/usao/pae/News/Pr/2005/jul/CMMC.html (describing
hospital's agreement to hire a consultant to review the facility's use of restraints).
119 See MEDICARE PAYMENT ADVISORY COMM'N, A DATA BOOK: HEALTHCARE SPENDING
AND THE MEDICARE PROGRAM 59 (2003), available at http://www.medpac.gov/
publications/congressional-reports/Jun03DataBookEntire report links.pdf (projecting that
Part A Trust Fund will become insolvent in 2026, and costs may exceed tax revenues as soon
as 2013).
120 42 U.S.C. § 1395w-4(g)(2)(C) (2000) (defining the "limiting charge").
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the Secretary of HHS is authorized to use a portion of the funds collected in
the proceeding to "make a payment to a beneficiary ... in the nature of
restitution for amounts paid by such beneficiary" that were found to be
excessive. 121
In criminal prosecutions under the health care fraud, mail fraud, and
wire fraud statutes, even broader authority supports compensation.
22
Under Title 18 of the United States Code, restitution is a mandatory
component of sentencing for "offense against property" and in cases "in
which an identifiable victim or victims has suffered a physical injury or
pecuniary loss. ' ' 123 In prosecutions under the Anti-Kickback Statute 124 and
other health care fraud offenses found in Title 42 of the United States Code,
restitution may be ordered as a part of a plea bargain or as a condition of
probation or supervised release. 25 The expenses subject to restitution are
defined broadly to include not only financial losses but also the costs of
necessary medical care, including psychiatric, psychological, and certain
"nonmedical care and treatment., 126 To the extent they remain applicable,
the federal Sentencing Guidelines also permit an increase in offense level
(and hence a more severe sentence) if the crime involves a vulnerable
victim, the abuse of a position of trust, or the use of a special skill, as well
as upward departures in sentences for crimes resulting in death, physical
121 Id. § 1395u(j)(4). The portion of FCA recoveries awarded for restitution is exempt
from allocation to the Trust Fund, thus preventing a direct conflict between the needs of
victims and the financial goals of federal prosecutors. See id § 1395i(k)(2)(C)(iv)
(exempting restitution amounts from transfer to the Control Account).
122 See 18 U.S.C. §§ 1341, 1343, 1346-47 (2000) (defining mail, wire, and health care
fraud).
123 Id. § 3663A(c)(1)(A)(ii), (B) (listing crimes for which restitution must be ordered);
U.S.S.G. § 5El. 1(2005) (providing for restitution under the federal Sentencing Guidelines);
see also id. § 8B 1.1 (restitution for corporate defendants). Mandatory restitution does not
apply to offenses against property, however, if
the number of victims is so large as to make restitution impracticable; or determining complex
issues of fact related to the cause or amount of the victim's losses would complicate or prolong
the sentencing process to a degree that the need to provide restitution to any victim is outweighed
by the burden on the sentencing process.
18 U.S.C. § 3663A(c)(3); see also U.S.S.G. § 5E1.1(B)(2).
124 42 U.S.C. § 1320a-7b(b).
125 See 18 U.S.C. § 3556 (order of restitution); id § 3563 (conditions of probation); id. §
3583 (conditions of supervised release after imprisonment); id. § 3663 (discretionary
restitution authority).
126 Id. § 3663(b)(2)(A). For certain drug offenses in which there is no identifiable
victim, restitution "based on the amount of public harm caused by the offense" is paid to the
state agencies that administer crime victim assistance and federal substance abuse block
grants. Id. § 3663(c); U.S.S.G. § 5El.l(d).
2006]
JOAN H. KRA USE
injury, or extreme psychological injury. 12 7 Thus, in criminal health care
fraud cases, restitution likely will be an available remedy. Unfortunately,
many health care fraud cases involve civil and administrative causes of
action that do not independently provide for restitution. As a result, most
health care fraud recoveries are destined for the Trust Fund and Control
Account, rather than for the individual patient victims.
C. WHITE COLLAR CRIME AND RECOGNITION OF PATIENT HARM
The lack of emphasis on patient harm, especially non-financial harm,
is also related to the white collar crime context in which health care fraud is
prosecuted. The DOJ has defined white collar crime as
[nionviolent crime for financial gain committed by means of deception by persons
whose occupational status is entrepreneurial, professional or semi-professional and
utilizing their special occupational skills and opportunities; also, nonviolent crime for
financial gain utilizing deception and committed by anyone having special technical
and professional knowledge of business and government, irrespective of the person's
• 128
occupation.
This definition limits both the universe of individuals who will be
subject to prosecution and the actionable forms of harm. Health care fraud
fits this definition because the goal of the fraud is to obtain unlawful
financial gain by means of deception, and because such fraud is
accomplished by persons who utilize their specialized status, training, and
knowledge of health care and the relevant reimbursement rules. 129 The fit is
an imperfect one, however, as the definition does not encompass the full
range of consequences from fraudulent activities, particularly to patients.
The emphasis on the financial goals of the scheme, in particular, suggests
not only that other forms of injury (physical and intangible) are irrelevant' 30
but also that the focus is on the primary victim-in this case the federal
health care programs. Under such a calculus, there is little incentive to
127 See U.S.S.G. §§ 3AL.1, 3B1.3, 5K2.1-2.3; United States v. Booker, 543 U.S. 220
(2005) (overturning mandatory nature of Federal Sentencing Guidelines).
128 Strader, supra note 7, at 1207-08 (quoting U.S. DEP'T OF JUSTICE, BUREAU OF JUSTICE
STATISTICS: DICTIONARY OF CRIMINAL JUSTICE DATA TERMINOLOGY 215 (2d ed. 1981)).
129 See also Bucy, Fraud by Fright, supra note 10, at 870-71 (noting, "Fraud by health
care providers shares three essential features of all white collar offenses: first, it has a hybrid
criminal/civil nature; second, it is difficult to investigate and prove; and third, successful
prosecution necessitates a careful development of a theory of the case that accomplishes
certain goals").
130 See Jennifer S. Recine, Note, Examination of the White Collar Crime Penalty
Enhancements in the Sarbanes-Oxley Act, 39 AM. CRIM. L. REv. 1535, 1559-60 (2002)
(noting that "optimal penalty theorists," such as Richard Posner, suggest that "white-collar
criminals do not pose a threat of physical harm to the public") (citing Richard A. Posner,
Optimal Sentences for White-Collar Criminals, 17 AM. CRIM. L. REV. 409, 409-10 (1980)).
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characterize cases in a patient-focused way, and little urgency to seek
compensation for individual patients with small-dollar (let alone intangible)
injuries. In the words of one former prosecutor, "[b]ecause the legal
theories historically used to prosecute health care providers have failed to
identify the patients as fraud victims, the powerful evidence that a provider
delivered poor medical care has seldom been used to its maximum
advantage.",
131
Despite the emphasis on financial gain, it has been recognized "that
white-collar crimes, particularly corporate crime, may have violent
consequences."' 32  This is perhaps acknowledged most clearly for
environmental crimes, which have the potential to cause harm to large
numbers of people. 133 While recognition that financially motivated crimes
may have physical consequences is a welcome step, it still does not capture
the essence of the problem in the health care context. Due to the underlying
medical nature of the activities, the potential for physical harm is in many
ways a defining characteristic of health care fraud. 134  The fact that the
misuse of individual patient information is not merely a foreseeable
consequence of the scheme but is in many ways a precondition to its
success makes health care fraud very different from other crimes in which
unknown individuals may, at some future point, suffer harm from causes
such as environmental toxins, workplace hazards, or substandard products.
Where the success of the fraud is linked so closely to the perpetrator's
ability to affect an individual patient's medical care, or at the very least to
utilize individual patient information, it is troubling that this harm remains
131 Bucy, Fraud by Fright, supra note 10, at 928. As a practical matter, however, a
patient-centered focus might offer distinct prosecutorial advantages. See id. (noting that "[a]
prosecutor able to identify a patient as a victim of the fraud will present a more complete
picture of the scope of the provider's fraud and thus will have a stronger case").
132 Elizabeth Szockyj, Imprisoning White-Collar Criminals?, 23 S. ILL. U. L.J. 485, 487
(1999) (noting that physical costs of white collar crimes include "[p]ersonal injuries,
diseases, and death due to occupational workplace hazards, environmental pollution, and the
marketing of dangerous products"). Some theorists clarify that white collar crime is crime
committed by non-violent means, although it may have violent effects. See, e.g., Gilbert
Geis, White-Collar Crime - What Is It?, in WHITE-COLLAR CRIME RECONSIDERED 31, 39
(Kip Schlegel & David Weisburd eds., 1992) (describing American Bar Association
definition of "economic" crime).
133 See, e.g., 42 U.S.C. § 6928(e) (2000) (specifying penalties for persons who
knowingly endanger others by their handling of hazardous waste); Neal Shover & Aaron S.
Routhe, Environmental Crime, 32 CRIME & JUST. 321, 322, 329-30 (2005) (noting "the
financial and human costs of environmental crime," as well as the difficulty of ascertaining a
dollar value for harm to non-human victims); Szockyi, supra note 132, at 487 (providing
examples of environmental harms).
134 See Bucy, Crimes by Health Care Providers, supra note 44, at 660 ("Health care
fraud is unique among white collar crimes in its ability to cause physical harm.").
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undervalued. For that reason, alternate recovery mechanisms may need to
be drawn from sources outside the white collar crime enforcement
framework.
III. DEVELOPING A PATIENT-CENTERED APPROACH TO FRAUD RECOVERY
The fact that compensation of patient injuries has not been a key
component of fraud recoveries to date does not mean that such an approach
is infeasible. Even within the limits imposed by HIPAA, alternative
settlements may be possible. When these tactics are combined with
approaches taken in other contexts, such as consumer class actions-
particularly given the flexibility traditionally accorded to state governments
in crafting compensation for injured individuals-there appears to be ample
leeway to structure settlements that more directly benefit patients without
significantly reducing the federal share of recovery.
A. RECENT FEDERAL SETTLEMENTS
On occasion, federal prosecutors have undertaken direct efforts to
return money to individual victims of health care fraud. Among the most
prominent examples was the "72-Hour Window Project," a national
investigation of hospitals that submitted separate Medicare bills for
outpatient services (usually laboratory tests) provided within 72 hours of a
related inpatient admission-services that, by law, are included in the lump-
sum hospital inpatient payment. 135 As a result, patients were charged
copayments for the additional outpatient services, rather than only their
share of the inpatient costs. The settlements required the hospitals to
reimburse patients for the improperly collected amounts. 136 Restitution
appears to have been feasible due to the limited universe of claims for
which each hospital was audited, making it possible to identify both the
patient victims and the amounts by which they were overcharged.
Even where the victim population is significantly larger, federal
prosecutors may have some ability to craft patient-centered settlements.
For example, the Civil Injunction Statute, which permits the Attorney
General to commence a civil action to enjoin a defendant from committing
135 See 42 C.F.R. § 412.2(c)(5) (2005) (defining certain preadmission services as
included in inpatient prospective payment); U.S. GEN. ACCOUNTING OFFICE, MEDICARE:
APPLICATION OF THE FALSE CLAIMS ACT TO HOSPITAL BILLING PRACTICES 3 (1998)
[hereinafter GAO, MEDICARE] (describing project).
136 See, e.g., GAO, MEDICARE, supra note 135, at 9 (describing settlements); Settlement
Agreement 10, United States v. Miss. Baptist Med. Ctr. (Oct. 10, 1999), cited in
COMPLIANCE REP. (CCH) 130,318 (requiring hospital to refund copayments and
deductibles to patients).
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a health care offense, authorizes the court to "take such... action, as is
warranted to prevent a continuing and substantial injury to the United States
or to any person or class of persons for whose protection the action is
brought."'1 37 Federal prosecutors have suggested that this statute provides
the basis for broad remedies in health care fraud cases, which could include
some form of restitution.1 38 Perhaps the most prominent public use of this
tactic to date has been in United States v. Merck-Medco Managed Care, in
which the government sought an injunction against fraudulent activities by
a mail order pharmacy company that included "shorting" prescriptions by
delivering too few pills and "switching" patients to alternate drugs for
which the company received financial benefits (including alternate drugs
manufactured by its parent company, Merck). 39 As part of the federal
Consent Order, Medco was required to reimburse patients for all out-of-
pocket costs for health care services incurred in connection with the
unauthorized switches.
140
Similar flexibility may be afforded by 18 U.S.C. § 3573, which
permits the government to petition for a remission of a criminal fine under
certain circumstances.14  In October 2003, for example, United Memorial
Healthcare Association ("UMH") pleaded guilty to one count of mail fraud
in connection with an investigation of a physician who was convicted of
performing medically unnecessary procedures at a UMH pain clinic. 142 In
an interesting procedural turn, the plea was deferred by the presiding judge,
which enabled the government to petition for remission of the fine. Using
the flexibility afforded by the remissions statute, the U.S. Attorney's Office
agreed to match up to $500,000 of the criminal fine, with the money
designated for a specific patient-directed purpose: funding a program
sponsored by UMH's new owner to provide health care and health
education services to disadvantaged individuals in the hospital's service
137 18 U.S.C. § 1345 (2000).
138 Conversation with James G. Sheehan, Associate U.S. Attorney, E. Dist. of Pa., in
Wilmington, Del. (June 6, 2003); see, e.g., Entry of Consent Decree at * 1, United States v.
Corson, No. 93-CV-3637, 1993 WL 332268 (E.D. Pa. July 12, 1993) (requiring physician,
under 18 U.S.C. § 1345, to reimburse Medicare beneficiaries who were overcharged for his
services).
139 See Amended Complaint, United States v. Merck-Medco Managed Care, No. 00-737
(E.D. Pa. Dec. 9, 2003); Consent Order for Permanent Injunction, United States v. Merck-
Medco Managed Care, No. 00-737, 2004 WL 977210 (E.D. Pa. 2004).
140 Consent Order, Merck-Medco Managed Care, 2004 WL 977210, at *7.
141 18 U.S.C. § 3573 (permitting judge to modify or remit an unpaid fine or assessment);
Telephone Interview with Glenn Martin, Assistant U.S. Attorney, Western District of
Michigan (Nov. 6, 2003).
142 Press Release, W. Dist. of Mich. Dep't of Justice, Matching Fund Program to Provide
Indigent Medical Care (Oct. 6, 2003) (attaching Matching Fund Agreement).
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area. 1 43 The agreement essentially allowed UMH to pay only half the fine,
but directed those funds (plus an equal amount of government funds)
specifically to improve the health of indigent people in the population.
While this strategy did not attempt to compensate any of the individual
patients who were harmed by the unnecessary procedures, it did accomplish
an important health-related goal by extending health care services to a
disadvantaged local community. However, it is clear that devising such an
alternative path for the funds required extreme procedural steps, as well as
the cooperation of both prosecutors and the presiding judge. While
intriguing, these examples may not provide an adequate model for large-
scale alternative settlements.
B. LESSONS FROM CONSUMER PROTECTION
The limited options available to federal prosecutors stand in stark
contrast to the broad consumer protection remedies available to state
attorneys general, who have been able to craft innovative health care fraud
settlements that target-at times with near poetic elegance-the
disadvantaged patient populations. For example, in settlements with drug
and medical device manufacturers accused of illegally excluding Medicare
and Medicaid patients from their marketing promotions (usually in an
attempt to avoid liability under the Anti-Kickback Statute), the
Massachusetts Attorney General has required the defendant companies to
donate free products to indigent patients in the state. 144  In Utah, a
pediatrician accused of charging private insurers for vaccines that were
supposed to have been given away to indigent children paid $64,000 to
settle the claims, with the money earmarked for a vaccination program
143 Id. (citing the Matching Fund Agreement 6).
144 See, e.g., Press Release, Commonwealth of Mass. Office of the Attorney Gen., N.J.
Pharmaceutical Corporation Settles with Attorney General: 21,000 Nitroglycerin Patches to
be Distributed Free to Public (May 21, 1995) (on file with author) (describing settlement
with Schering Corporation, which agreed to distribute free Nitro-Dur patches to state public
hospitals); Press Release, Novo Nordisk, Novo Nordisk and Massachusetts Extend NovoPen
1.5 Delivery System Promotion to Medicaid Patients (Mar. 19, 1997) (on file with author)
(announcing company's agreement to provide hundreds of free insulin delivery systems to
indigent and Medicaid patients at certain hospitals in the state); see also Press Release,
Attorney Gen. Bob Butterworth, Humana Medical Plan to Refund $800,000 to Settle
Allegations (Feb. 16, 2000) (requiring Medicare HMO to refund money to beneficiaries who
were overcharged for hearing aids), available at http://myfloridalegal.com/newsrel.nsf/
newsreleases/AAECA64080033E5085256887004AC291?OpenDocument (last visited Apr.
3, 2006).
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administered by the state.1 45 In Connecticut, drug manufacturer Dey Inc.
settled pricing fraud allegations, in part, by donating $800,000 of its
respiratory drugs to community health centers and other free clinics in the
state. 46 Such settlements clearly confer a financial benefit on the state and
local governments, which otherwise would be required to purchase similar
items for publicly funded hospitals and health care programs. But more
importantly, these settlements impose sanctions that are tailored to the
underlying harm, making the previously denied products available to a
disadvantaged population within the state. This more holistic approach to
remedying the effects of fraud confers an advantage on those who were
disadvantaged-if not the exact victims, then at least patients who are
similarly situated.
While some of these settlements may hinge on specific state anti-fraud
laws, conceptually they are drawn from a rich history of consumer
protection lawsuits, especially class actions. Indeed, many of the factors
that have driven the development of these doctrines pose equally vexing
problems in health care fraud cases. In the antitrust and consumer
protection arenas, for example, it has been possible to devise workable
remedies in cases involving large numbers of potential victims, even where
it is difficult to identify all injuries and where individual recoveries are
likely to be small. 147 In such cases, commentators have argued in favor of
more "fluid" forms of recovery that can meet the twin goals of benefiting
injured consumers and forcing the wrongdoer to disgorge its ill-gotten
gains 148 -goals that resonate with equal urgency in the health care fraud
context.
145 Press Release, Utah Attorney Gen. Mark Shurtleff, Doctor Pays Up for Selling Free
Vaccine (Oct. 21, 2005), available at http://attomeygeneral.utah.gov/PrRel/
proctober212005.htm.
146 Dey Inc. Settles Overcharge Case Filed by Connecticut AG, Will Pay $1.7M, 9
HEALTH CARE FRAUD REP. (BNA) 614 (2005).
147 See Gail Hillebrand & Daniel Torrence, Claims Procedures in Large Consumer Class
Actions and Equitable Distribution of Benefits, 28 SANTA CLARA L. REv. 747, 750 (1988)
(noting that "[a] hallmark of the consumer class action is large class size and relatively small
damages per class member"). Note that the feasibility of such actions in the future will be
affected by the Class Action Fairness Act of 2005, which addresses not only the jurisdictions
in which such suits may be brought but also the structure of non-monetary remedies,
particularly coupons. Pub. L. No. 109-2, 119 Stat. 4 (2005).
148 See, e.g., Hillebrand & Torrence, supra note 147, at 762-63 (noting that fluid
recovery assures the disgorgement of illegal profits and "ensure[s] that the class will in fact
receive benefits, whether direct or indirect, of some minimum amount"); Michael Malina,
Fluid Class Recovery as a Consumer Remedy in Antitrust Cases, 47 N.Y.U. L. REv. 477
(1972) (describing fluid distribution of remainder after compensation of direct claims of
harm in antitrust suit); James R. McCall et al., Greater Representation for California
Consumers-Fluid Recovery, Consumer Trust Funds, and Representative Actions, 46
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Although fluid recovery may include mechanisms such as coupons,
price rollbacks, or medical monitoring, the more relevant approaches for
our purposes require deposit of all or part of the recovered money into a
designated fund-accomplished, for example, by escheat to a general or
specific state account, or by the establishment of a new consumer fund.
149
This is most often accomplished through application of the equitable
doctrine of cy pres, in which settlement funds that cannot be delivered
directly to injured individuals are instead used for their "next best use" by
distributing them more generally, as through a consumer trust fund, to
subsidize related consumer protection efforts. 150  Such funds "can be
structured to serve the purposes of the underlying litigation .... The benefit
takes the form of increased services to, or protection of rights of the entire
class, which is preferable to limiting benefits only to those who successfully
complete a claim."'5 1 The doctrine is most attractive in cases where:
(1) the class of consumers represented is large and practically unidentifiable; (2) the
individual damage suffered by each consumer is relatively small; (3) there are no
creative alternatives to provide value directly to consumers; and (4) the recipients who
will most likely benefit, albeit indirectly, are the consumers in whose name the
original action is brought. 1
52
HASTrNGS L.J. 797, 807-12 (1995) (describing fluid forms of recovery in consumer class
actions); Miller & Singer, supra note 116, at 102-07 (dividing "nonpecuniary settlements"
into coupon settlements, monitoring settlements, securities settlements, reverter fund
settlements that return excess funds to the defendant, and fluid recovery settlements); Anna
A. Durand, Note, An Economic Analysis of Fluid Class Recovery Mechanisms, 34 STAN. L.
REV. 173 (1982) (arguing in favor of nonprice fluid recovery mechanisms). One impediment
to the application of these principles in the health care fraud context may be the necessity
that each class member suffer similar harm. See Malina, supra, at 488 (requiring that
damage be "identical, if not in dollar amount, then in common percentage or like measure").
149 See, e.g., McCall et al., supra note 148, at 808-10 (describing fluid recovery
mechanisms of price rollback, general escheat, earmarked escheat, and the establishment of a
trust fund). Under this framework, note that the current HIPAA Control Account
mechanism resembles a federal form of earmarked escheat.
150 Historically, the doctrine of cy pres permitted a court to avoid invalidation of a
charitable trust when the testator's conditions could not be satisfied. As the California
Supreme Court explained, "[w]here compliance with the literal terms of a charitable trust
became impossible, the funds would be put to 'the next best use,' in accord with the
dominant charitable purposes of the donor." California v. Levi Strauss & Co., 715 P.2d 564,
570 (Cal. 1986). For a discussion of the cy pres doctrine in the antitrust and consumer
protection contexts, see, for example, Susan Beth Farmer, More Lessons from the
Laboratories: Cy Pres Distributions in Parens Patriae Antitrust Actions Brought By State
Attorneys General, 68 FoRD. L. REV. 361 (1999).
151 Hillebrand & Torrence, supra note 147, at 766.
152 Farmer, supra note 150, at 365 (setting forth factors relevant to cypres remedies in
parens patriae antitrust actions).
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While the cy pres approach initially contemplated disbursement for a
purpose closely related to the origin of the funds, courts have recognized
that the modem doctrine "permit[s] use of funds for other public interest
purposes by educational, charitable, and other public service organizations"
more tangentially related to the original harm. 
153
One of the key questions is whether this mechanism can be used to
distribute an entire award, or whether it is limited to disposing of the
remainder once the claims of identified class members have been satisfied.
The latter use appears to be more common, as it prevents the non-
compensatory (and potentially anti-deterrent) effects of returning the
remaining funds to the defendant or having them escheat to a general state
fund.' 54  In a class action suit against Toshiba for the sale of allegedly
defective computers, for example, the court ordered that funds remaining
after all individual claims were exhausted be distributed to a charity, which
in turn would use the funds to purchase computers for distribution to
"schools, churches, non-profit organizations, libraries, hospitals, and the
poor."' 55 Thus, even if full compensation is not available, cypres makes it
153 Superior Beverage Co. Inc. v. Owens-Illinois, Inc., 827 F. Supp. 477, 479 (N.D. 111.
1993).
154 See Hillebrand & Torrence, supra note 147, at 762 (noting that "[f]luid recovery is
generally used to distribute the residue of a fund created by settlement or judgment when the
claims rate is less than 100%"); McCall et al., supra note 148, at 850-51 (calling on
plaintiffs' counsel to recommend fluid recovery for the undistributed portion of an award to
"ensure that the funds will be used either to promote the purposes of the statutory
prohibitions to be enforced or to protect the interests of the persons injured by the illegal
conduct").
155 Shaw v. Toshiba Amer. Info. Sys., Inc., 91 F. Supp. 2d 942, 981 (E.D. Tex. 2000);
see also Patricia Studevant, Using the Cy Pres Doctrine to Fund Consumer Advocacy,
TRIAL, Nov. 1997, at 80 (advocating use of cypres distribution to fund advocacy efforts). A
similar approach may be used for punitive damages in states with split-recovery statutes
directing a portion of such damages to victim compensation funds. See DeMendoza v.
Huffman, 51 P.3d 1232 (Or. 2002) (upholding Oregon Revised Statute § 18.540, which
allocates 60% of punitive damage awards to the Criminal Injuries Compensation Account).
The success of these statutes has spurred proposals for broader use of the mechanism for "a
societal compensation goal: the redress of harm caused by defendants who injure persons
beyond the individual plaintiffs in a particular case." Catherine M. Sharkey, Punitive
Damages as Societal Damages, 113 YALE L.J. 347, 351-52 (2003) (suggesting that the
Supreme Court's recent decision overturning a massive punitive damages award in State
Farm Mutual Automobile Insurance Co. v. Campbell, 538 U.S. 408 (2003), may have
unwittingly authorized this alternative). Such goals would be achieved, for example, by the
statutory allocation of a portion of the punitive damage award to state funds created to
address the type of harm caused by the defendant's activities, or to nonprofit organizations
pursuing similar goals. Id. at 420-21; Dede W. Welles, Charitable Punishment: A Proposal
to Award Punitive Damages to Nonprofit Organizations, 9 STAN. L. & POL'Y REv. 203, 205,
210 (1998) (arguing in favor of funding targeted activities that are likely to benefit victims,
rather than society more generally).
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possible to achieve some measure of rough justice. Disbursing an entire
settlement via a cy pres mechanism, however, has proven to be more
controversial. As one commentator notes, "unless the costs of distribution
are overly burdensome, it is preferable to distribute settlement funds
directly to consumers rather than to put the entire fund to a related use that
will only indirectly benefit those who were injured by the violation
alleged."'' 56 As such, this option has been reserved for cases in which the
compensation of individual class members appears to be unrealistic due to
the size of the class and the small amount of each award. 1
57
Despite these uncertainties, it is intriguing to consider whether this
approach might be applied to health care fraud recoveries. The mechanism
would appear particularly well-suited to situations in which the harm
suffered by patients is diffuse and intangible, rather than discrete and of a
serious nature. Of course, there are significant differences between
consumer protection and antitrust suits and health care fraud enforcement
actions (not the least of which is the lack of an enabling statute permitting
the use of such remedies). 58 Nonetheless, to the extent these disbursement
options represent the "next best use" of settlement funds by advancing both
consumer protection and deterrence goals, they address many of the same
issues seen in health care fraud cases and might provide a fruitful avenue
for future patient compensation efforts.
C. PATIENT-CENTERED STRATEGIES FOR HEALTH CARE FRAUD
RECOVERY
The state and federal governments already have begun to work
together to apply these strategies in health care fraud cases. In the Merck-
Medco litigation described above, for example, Medco negotiated a
separate consent order with the Attorneys General of twenty states pursuant
156 Farmer, supra note 150, at 394.
157 See, e.g., New York v. Reebok Int'l Ltd., 96 F.3d 44, 49 (2d Cir. 1996) (approving
broader distribution "[blecause of the unlikelihood of there being any significant 'net
monetary relief' for individual claimants if an attempt were made to distribute the settlement
proceeds among them," due to the large number of claimants and the minimal injury suffered
per shoe purchase).
158 Another key difference is the government's role. In consumer protection or parens
patriae antitrust actions, for example, the states sue on behalf of their injured citizens. See
15 U.S.C. § 15c (2000) (permitting parens patriae suits under the federal antitrust statutes);
Richard P. leyoub & Theodore Eisenberg, State Attorney General Actions, The Tobacco
Litigation, and the Doctrine of Parens Patriae, 74 TuL. L. REv. 1859, 1863 (2000) (noting
that in "parens patriae actions ... a state may recover costs or damages incurred because of
behavior that threatens the health, safety, and welfare of the state's citizenry"). In contrast,
many health care fraud cases are brought on the government's own behalf as a defrauded
payer. See supra notes 112-16 and accompanying text.
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to which the company additionally agreed to pay: (1) $6.6 million, to be
used for "attorney's fees and investigative costs, consumer education,
litigation, public protection purposes or local consumer aid funds;"' 59 (2)
$2.5 million, to reimburse consumers up to $25 each for expenses incurred
in connection with a particular cholesterol drug switch scheme; 160 and (3)
$20 million, for the affected states to distribute via a cy pres mechanism to
state agencies or programs, nonprofit corporations, or charitable
organizations "to benefit low income, disabled, or elderly consumers of
prescription medications, to promote lower drug costs for residents of that
State, to educate consumers concerning the cost differences among
medications, or to fund other programs reasonably targeted to benefit a
substantial number of persons affected by the" conduct at issue.
161
A similar approach was taken against pharmaceutical manufacturer
Warner-Lambert, which was accused of extensive civil and criminal
conduct in connection with the marketing of its drug Neurontin. 162  The
company pled guilty to two counts of violating the federal Food, Drug &
Cosmetic Act by "misbranding" the drug and agreed to a $240 million
criminal fine, as well as a civil FCA fine of $83.6 million for the federal
portion of relevant Medicaid losses. 163 In a separate settlement with the
states, the company also agreed to pay $68.4 million plus interest for losses
caused to the state Medicaid programs, as well as $38 million to fund a
consumer protection program to remedy the harm caused by the improper
marketing efforts.164 Under the terms of the state settlement, $6 million of
the consumer fund was earmarked for the development of a National
Advertising Program to provide information to prescribers regarding the
appropriate use of Neurontin and similar drugs, and $21 million was
designated for grants to "national programs, regional programs, or programs
in individual states or in a group of states, relating to prescriber and
159 Consent Order at 24, State v. Medco Health Solutions, Inc., No. CV-04 (Me. Super.
Ct. Apr. 26, 2004) (on file with author).
160 Id. at 18-19.
161 Id. at 21. As an alternative to a monetary payment, states were permitted to receive
pharmaceuticals (of equivalent value plus 25%) from Medco in bulk and/or via the provision
of prepaid generic drug cards. Id. at 22-23.
162 See Press Release, U.S. Dep't of Justice, Warner-Lambert to Pay $430 Million to
Resolve Criminal & Civil Health Care Liability Relating to Off-Label Promotion (May 13,
2004), available at www.usdoj.gov/usao/ma/presspage/May2004/Warner-Lambert-
globalsettlemnt.htm.
163 Id (noting that the violation was a felony due to the company's prior, unrelated
FDCA convictions); Food, Drug & Cosmetic Act, 21 U.S.C. § 301 (2000).
164 In re Warner-Lambert Company LLC, Assurance of Voluntary Compliance, available
at http://209.190.248.167/upload/1084551748_Assurance-of VoluntaryCompliance.pdf
(last visited Dec. 23, 2005).
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consumer education regarding drug information, drug marketing, and the
conditions for which drugs are prescribed."' 165  The government's
sentencing memorandum noted the unique nature of this remedy, stating
"the proposed resolution does include a significant state consumer
protection component, which has not routinely been part of prior health care
fraud settlements arising out of federal Department of Justice
investigations."1
66
Several things are notable about these recent efforts. First, the fact that
they arose in the pharmaceutical context was not a coincidence. Not only is
the pharmaceutical industry under intense scrutiny regarding drug pricing
and promotional activities, 167 but the fraud alleged in these cases
contributed to the types of patient harm most easily addressed via a cy pres
mechanism: widespread, often intangible harm to a diffuse population of
patients whose care may have been affected (coupled, in the Merck-Medco
litigation, with discrete financial harm to a large but identifiable
subpopulation). Given the huge nationwide market for prescription drugs,
the direct financial impact of pricing fraud on patients, and the potential for
significant consumer confusion from improper marketing campaigns, this is
a particularly attractive context in which to test a cy pres remedy. Second,
it is notable that neither the federal nor state governments were able to
achieve these settlements alone; only by banding together were prosecutors
able to combine the flexibility of state consumer protection efforts with the
threat of severe federal sanctions for fraud. In accordance with HIPAA, no
portion of the federal recovery was diverted to compensate patients-
Medco agreed to an injunction against the disputed conduct, and Warner-
Lambert paid a hefty fine in direct settlement of the federal civil and
criminal fraud allegations. Without the participation of the states, therefore,
significantly less money would have been directed toward patients. While
the results were extremely favorable for consumers, they appear to be
feasible only in fraud investigations that similarly merit extensive joint
enforcement efforts.
165 id.
166 Sentencing Memorandum of the United States at 43 n.10, United States v. Warner-
Lambert Company LLC, No. 04-10150 RGS (D. Mass. May 13, 2004) (on file with author).
167 See, e.g., In re Pharma. Indus. Average Wholesale Price Litig., 230 F.R.D. 61 (D.
Mass. 2005) (resolving class certification issues in suit brought by consumers and third-party
payers against pharmaceutical companies). Moreover, with the advent of the new Medicare
Prescription Drug Benefit in January 2006, the federal government has an even stronger
interest in prescription drug fraud. See 42 U.S.C. § 1395w-101 (2000 & Supp. 2005);
Enforcement Officials Detail New Weapons, Concerns Posed by New Medicare Rx Benefit,
14 HEALTH L. RPTR. (BNA) 947 (2005) (describing heightened opportunities for fraud in
new program, as well as new enforcement plans).
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Whether these strategies can be applied more broadly remains to be
seen. Current class action and consumer protection mechanisms may well
be sufficient for situations in which discrete harm is suffered by an
identifiable population of patients, such as harm arising from prescription
drug price manipulation. 68 In such cases it may well be more efficient to
leave the existing procedures in place, rather than create an additional level
of federal bureaucracy. In other situations, however, the harm to patients
may be so diffuse or intangible that broader fluid recovery will be superior
to traditional class action mechanisms. For example, one of the allegations
in the Warner-Lambert litigation was that the company marketed Neurontin
"off-label," for conditions for which the drug had not been approved by the
Food and Drug Administration (and, in fact, for one condition for which
approval explicitly had been denied).1 69 Because the off-label restrictions
limit only the manufacturer's promotion of the drug, rather than a
physician's use of the drug, physicians generally may prescribe an approved
drug for any condition, even an unapproved one. 170 Compared to pricing
fraud, where it safely can be assumed that any consumer who paid above a
certain price for the drug was harmed, identifying the victims of an off-label
promotional scheme is much more difficult. In the Warner-Lambert case,
this would not simply have required the identification of all patients who
received Neurontin, but rather the identification of those patients who were
prescribed the drug for an off-label purpose (which likely would require
review of individual medical records)-as well as consideration of the
perhaps unanswerable question of whether the prescribing physician was
influenced by Wamer-Lambert's marketing efforts or would have
prescribed the drug off-label anyway in his/her independent medical
judgment. Given this daunting prospect, it is no wonder that a broader
consumer fund approach was considered to be appropriate.
Moreover, it is possible that federal health care program beneficiaries
are harmed in unique ways by health care fraud. Because many
beneficiaries live on fixed incomes, fraud schemes that overcharge for
health care items and services may have particularly detrimental effects.171
168 See, e.g., In re Cardizem CD Antitrust Litig., 218 F.R.D. 508, 516 (E.D. Mich. 2003)
(describing plan for compensating consumers who overpaid for a drug due to illegal anti-
competitive agreements by manufacturers to keep cheaper generic versions of the drug off
the market).
169 See Sentencing Memorandum, supra note 166, at 10, 13-26 (documenting centralized
decisions to engage in off-label marketing, as well as failed attempt to gain approval for the
use of Neurontin as solo therapy for epilepsy).
170 Id. at 10.
171 Anecdotes abound about the difficulties of paying for medical care in addition to
other necessities. See, e.g., Roger Alford, More Seniors Jailed for Prescription Drug Sales,
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Similarly, medically frail beneficiaries may be at greater risk of harm from
fraudulent schemes with physical effects, such as those involving
unnecessary diagnostic tests. 172  Indeed, there may even be a unique,
intangible injury that arises from being targeted solely due to one's status as
a federal health care program beneficiary. While a discussion of these
subjects is beyond the scope of this Article, it is worth noting that
beneficiaries may not fully be compensated even by traditional consumer
remedies.
How might beneficiary harm be addressed? At a minimum, direct
compensation should be available for patients who have suffered
identifiable harm. While Congress would need to enact a federal
mechanism for this purpose, a similar result may be achieved currently
through global resolutions that incorporate state-based consumer
compensation mechanisms, as in the Merck-Medco case. But what of less
tangible, or at least less demonstrable, forms of harm? Certainly, devoting
money to the education of vulnerable beneficiaries is a good investment,
but it may not be enough. An alternative might be to create a modified
form of consumer fund tailored to the unique types of injuries experienced
by federal health care program beneficiaries. Although beneficiaries who
suffer physical harm due to fraud schemes are fortunate in that they have
access to health care through the relevant federal health care programs, they
are likely to face new financial burdens in the form of additional
copayments and deductibles-not to mention the possibility of exceeding
their coverage limits, either due to actual medical needs or as an effect of
the fraudulent bills submitted in their names.1 73 A Beneficiary Copayment
Fund, for example, might be set aside for the payment of such expenses for
patients who can meet defined eligibility criteria. 174 Because it would be
HOUSTON CHRON., Dec. 12, 1995, at A39 (describing increases in arrests of Appalachian
senior citizens for selling their prescription drugs). As one law enforcement official noted,
"When a person is on Social Security, drawing $500 a month, and they can sell their pain
pills for $10 apiece, they'll take half of them for themselves and sell the other half to pay
their electric bills or buy groceries." Id. (quoting Floyd County jailer Roger Webb).
172 See, e.g., United States ex rel. Kneepkins v. Gambro Healthcare Inc., 115 F. Supp. 2d
35, 42 (D. Mass. 2000) (alleging performance of unnecessary blood tests).
173 See supra notes 69-72 and accompanying text.
174 Although beyond the scope of this Article, such a process could be modeled on that
used to disburse awards in mass products liability claims involving bankrupt corporations.
See, e.g., SETTLEMENT FACILITY AND FUND DISTRIBUTION AGREEMENT BETWEEN Dow
CORNING CORPORATION AND THE CLAIMANTS' ADVISORY COMMITTEE 1 (2004), available at
http://www.tortcomm.org/ downloads/SETTLEMENT FACILITYAGMT.pdf (last visited
Feb. 26, 2006) (setting forth breast implant claims settlement criteria and procedures). In the
health care fraud context, the criteria could be tailored so as to restrict the universe of
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unclear initially how many beneficiaries would incur such future liability,
this mechanism would perhaps most closely resemble the use of medical
monitoring funds in mass tort actions in which exposure to a toxic
substance may have increased the risk of future harm to an identifiable
population.175 Although the details of such a "fraud monitoring" fund are
beyond the scope of this Article, the mechanisms likely would be drawn
from an amalgam of existing consumer protection and mass tort litigation
strategies.
Clearly, congressional action would be necessary if the money for such
a fund came from the federal government's share of fraud recovery, since
the disposition of that money is tightly controlled by HIPAA. If federal
prosecutors were so inclined, however, they might be able to test this
strategy in individual cases through some of the mechanisms identified
above, such as the § 1345 civil injunction statute or the § 3573 remissions
provisions. In the alternative, creation of such a fund might be demanded-
or at least strongly encouraged-as an additional state or private mechanism
outside the official federal settlement process. However accomplished, the
use of a Beneficiary Copayment Fund mechanism on an experimental basis
is an option that should be considered.
IV. CONCLUSION
How can we make health care fraud recovery more patient-centered?
Amendments to current federal law, to permit either direct compensation of
injured patients or a broader co-payment fund, would most efficiently
achieve this goal. In the absence of such legislative changes, expanded use
of global federal-state negotiations, in which consumer protection remedies
are incorporated into the state settlements, remains the best option. To the
extent federal health care fraud cases provide an opportunity for creative
use of existing law to craft patient-centered remedies, as in the Medco suit,
such creativity should be encouraged-within DOJ and HHS, by Congress,
and in public debate. Without a congressional mandate to incorporate
patient-centered values into health care fraud settlements, however, the
success of such efforts will turn on prosecutorial priorities: on whether
prosecutors truly believe that "the bigger issues are what is happening to the
patients., 17
6
claimants to deserving beneficiaries, but far less onerous than those required to prove
causation in a tort suit, for example.
175 See Miller & Singer, supra note 116, at 103-04 (describing monitoring settlements as
a category of nonpecuniary fluid recovery).
176 James Sheehan, Biotech Fraud: Reality or Fantasy?, 2 HouS. J. HEALTH L. & POL'Y
11, 26 (2002).
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